Source: http://www.google.de/patents/US7780991
Timestamp: 2013-12-05 18:04:14
Document Index: 670041073

Matched Legal Cases: ['art 1', 'Application No. 82', 'Application No. 82', 'Application No. 87501509', 'Application No. 63', 'Application No. 63']

Patent US7780991 - Solid dose delivery vehicle and methods of making same - Google PatenteSuche Bilder Maps Play YouTube News Gmail Drive Mehr » Erweiterte Patentsuche | Anmelden Erweiterte Patentsuche PatenteThe present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded...http://www.google.de/patents/US7780991?utm_source=gb-gplus-sharePatent US7780991 - Solid dose delivery vehicle and methods of making same Ver�ffentlichungsnummerUS7780991 B2PublikationstypErteilung AnmeldenummerUS 11/134,701 Ver�ffentlichungsdatum24. Aug. 2010Eingetragen20. Mai 2005 Priorit�tsdatum2. Dez. 1994Auch ver�ffentlicht unterUS6290991, US6331310, US6565871, US6811792, US6893657, US7056495, US7744925, US7785631, US20020012687, US20030054040, US20030147961, US20040052825, US20040219206, US20050276759, US20050276845, US20050276846, US20080193546 Ver�ffentlichungsnummer11134701, 134701, US 7780991 B2, US 7780991B2, US-B2-7780991, US7780991 B2, US7780991B2 ErfinderBruce J. Roser, Jaap Kampinga, Camilo Colaco, Julian BlairUrspr�nglich Bevollm�chtigterQuadrant Drug Delivery LimitedPatentzitate (101), Nichtpatentzitate (563), Referenziert von (1), Klassifizierungen (11), Juristische Ereignisse (1) Externe Links: USPTO, USPTO-Zuordnung, EspacenetSolid dose delivery vehicle and methods of making sameUS 7780991 B2 Zusammenfassung The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.
39. The therapeutic composition according to claim 38, said therapeutic particles further comprising and amino acid that is capable of inhibiting the Maillard reaction. Beschreibung
Patentzitate Zitiertes PatentEingetragen Ver�ffentlichungsdatum Antragsteller TitelUS12571416. Apr. 1872 Improvement in medical compounds or phosphated candiesUS5865046. Juli 189613. Juli 1897 Otto marcschUS97999327. Dez. 1910 Projectile.US18555913. Febr. 192626. Apr. 1932Wallerstein Co IncInvertase preparation and method of making the sameUS245703610. Apr. 194621. Dez. 1948Epstein Albert ACoffee concentrate and the process of producing itUS254930320. Apr. 194917. Apr. 1951Bristol Lab IncInhaler for crystalline pencilllin or the likeUS264860921. Jan. 194911. Aug. 1953Wisconsin Alumni Res FoundMethod of applying coatings to edible tablets or the likeUS33624056. Apr. 19649. Jan. 1968Hamilton O. HazelMethod and apparatus for admixing gas with solid particlesUS345605010. Dez. 196515. Juli 1969Boehringer & Soehne GmbhDragee preparationUS34804689. Febr. 196625. Nov. 1969Farmaceutici ItaliaProcess of preparing pharmaceutical tablet with orange-peel-like protective sugar coatingUS354098414. Juni 196817. Nov. 1970CalbiochemReagent material and method for creative kinase assayUS355476724. Febr. 196912. Jan. 1971Eberhard NurnbergCoated confectioneryUS355771717. Mai 196826. Jan. 1971Gen Mills IncProcess for making candy flossUS358349130. Jan. 19698. Juni 1971Serlachius OyPortable fire extinguisher constructionUS360806616. Juni 196921. Sept. 1971En Nom Collectif Science UnionPharmaceutical preparation based on bacterial antigensUS361929415. Juli 19689. Nov. 1971Penick & Ford LtdMethod of combining crystalline sugar with impregnating agents and products produced therebyUS363235729. Juli 19694. Jan. 1972Standard Brands IncMethod of producing hard candyUS365544227. Aug. 196911. Apr. 1972California & Hawaiian SugarMethod of making sugar and sugar productsUS36664963. Sept. 196930. Mai 1972Firmenich IncWater soluble,powdered,terpene-containing flavorsUS367490127. Apr. 19704. Juli 1972Nat Patent Dev CorpSurgical suturesUS36945475. Nov. 197126. Sept. 1972Lever Brothers LtdAnti-dandruff hair preparationUS374568228. Sept. 197117. Juli 1973Pneu Dart IncGun for propelling a drug or medicine projectileUS392163722. Juli 197425. Nov. 1975Bespak Industries LtdInhaler for powdered medicamentUS39376686. Nov. 197210. Febr. 1976Ilse ZolleMethod for incorporating substances into protein microspheresUS394826314. Aug. 19746. Apr. 1976Minnesota Mining And Manufacturing CompanyBallistic animal implantUS396448313. Jan. 197522. Juni 1976Syntex Puerto Rico, Inc.Inhalation deviceUS399176121. Okt. 197416. Nov. 1976Salvatore CocozzaInhaler for powdered medicamentsUS401818515. Dez. 197519. Apr. 1977Coors Container CompanyPowder feeder pick-up tubeUS403622320. Jan. 197619. Juli 1977Obert Jean ClaudeApparatus for generating aerosols of solid particlesUS40698195. Aug. 197624. Jan. 1978Societa Farmaceutici S.P.A.Inhalation deviceUS40982735. Nov. 19764. Juli 1978Syntex Puerto Rico, Inc.Inhalation deviceUS41029991. Juni 197725. Juli 1978Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiProcess for producing stable macromomycin powderUS410502726. Okt. 19768. Aug. 1978Syntex Puerto Rico, Inc.Inhalation deviceUS411461510. Dez. 197619. Sept. 1978Aktiebolaget DracoAerosol inhalation deviceUS412750210. Juni 197728. Nov. 1978Eastman Kodak CompanyStabilizers for reconstituted, lyophilized samplesUS412762219. Sept. 197528. Nov. 1978Eisai Co., Ltd.Process for the preparation of hollow particulatesUS415368915. Aug. 19778. Mai 1979Takeda Chemical Industries, Ltd.Stable insulin preparation for nasal administrationUS415738618. Mai 19785. Juni 1979Rochelle Paul JSoft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only by brushingUS415854417. Juli 197819. Juni 1979Beckman Instruments, Inc.Process for preparing a biological composition for use as a reference control in diagnostic analysisUS415931919. Apr. 197826. Juni 1979Bachmann Peter AMethod of preparing an attenuated transmissible gastroenteritis (TGE) virus strain for use in live vaccinesUS418059329. Apr. 197725. Dez. 1979Cohan Allan NProcess for producing round spherical free flowing blown bead food products of controlled bulk densityUS41923095. Sept. 197811. M�rz 1980Syntex Puerto Rico, Inc.Inhalation device with capsule openerUS421176917. Aug. 19788. Juli 1980Takeda Chemical Industries, Ltd.Preparations for vaginal administrationUS42275225. Sept. 197814. Okt. 1980Syntex Puerto Rico, Inc.Inhalation deviceUS42449496. Apr. 197813. Jan. 1981The Population Council, Inc.Manufacture of long term contraceptive implantUS424952612. Apr. 197910. Febr. 1981Fisons LimitedInhalation deviceUS425346814. Aug. 19783. M�rz 1981Steven LehmbeckNebulizer attachmentUS429482930. Juli 198013. Okt. 1981Teijin LimitedPowdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereofUS43059255. Mai 198015. Dez. 1981Behringwerke AktiengesellschaftLatex reagentUS432652430. Sept. 198027. Apr. 1982Minnesota Mining And Manufacturing CompanySolid dose ballistic projectileUS432707617. Nov. 198027. Apr. 1982Life Savers, Inc.Compressed chewable antacid tablet and method for forming sameUS432707729. Mai 198127. Apr. 1982Life Savers, Inc.Compressed chewable antacid tablet and method for forming sameUS433893128. Apr. 198013. Juli 1982Claudio CavazzaDevice for the quick inhalation of drugs in powder form by humans suffering from asthmaUS437155721. Jan. 19811. Febr. 1983General Foods CorporationMaintenance of protein quality in foods containing reducing sugarsUS437294213. Aug. 19818. Febr. 1983Beecham Inc.Candy base and liquid center hard candy made therefromUS44077869. Apr. 19814. Okt. 1983International Standard Electric CorporationGlass compositionUS442308616. Okt. 198027. Dez. 1983Roquette FreresProcess for hard coating with sorbitol and products obtained therebyUS444686230. Okt. 19808. Mai 1984Baum Eric ABreath actuated devices for administering powdered medicamentsUS445223924. M�rz 19815. Juni 1984Hilal MalemMedical nebulizing apparatusUS446298217. Sept. 198231. Juli 1984Tanabe Seiyaku Co., Ltd.Microcapsules and method of preparing sameUS448457712. Mai 198227. Nov. 1984Key Pharmaceuticals, Inc.Drug delivery method and inhalation device thereforUS450303514. Febr. 19835. M�rz 1985Hoffmann-La Roche Inc.Protein purification process and productUS453434327. Jan. 198413. Aug. 1985Trutek Research, Inc.Metered dose inhalerUS455132920. Jan. 19845. Nov. 1985Joan HarrisOral medicament lollipopUS458874427. Jan. 198113. Mai 1986Mchugh John EMethod of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalideUS45902063. Mai 198420. Mai 1986Fisons PlcInhalation pharmaceuticalsUS459155229. Sept. 198227. Mai 1986New York Blood Center, Inc.Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptideUS459931113. Aug. 19828. Juli 1986Kawasaki Glenn HGlycolytic promotersfor regulated protein expression: protease inhibitorUS46135009. M�rz 198423. Sept. 1986Teijin LimitedPowdery pharmaceutical composition for nasal administrationUS461727225. Apr. 198414. Okt. 1986Economics Laboratory, Inc.Enzyme drying processUS46208476. Mai 19844. Nov. 1986Vsesojuzny Nauchno-Issledovatelsky Institut Meditsinskikh PolimerovDevice for administering powdered substancesUS462425113. Sept. 198425. Nov. 1986Riker Laboratories, Inc.Apparatus for administering a nebulized substanceUS46274327. Okt. 19839. Dez. 1986Glaxo Group LimitedDevices for administering medicaments to patientsUS46562506. Aug. 19847. Apr. 1987Toyo Jozo Kabushiki Kaisha[Nle.sup.8, Nle.sup.18, Tyr.sup.34 or Phe.sup.34 ]-h-PTH peptide derivativesUS465969622. Apr. 198321. Apr. 1987Takeda Chemical Industries, Ltd.Pharmaceutical composition and its nasal or vaginal useUS467797516. Okt. 19857. Juli 1987The University Of AucklandMethod of dispensing and/or a dispenserUS468002712. Dez. 198514. Juli 1987Injet Medical Products, Inc.Needleless hypodermic injection deviceUS468471915. Mai 19854. Aug. 1987Ss Pharmaceutical Co., Ltd.α,α-trehalose fatty acid diester derivativeUS46983285. Dez. 19866. Okt. 1987The General Hospital CorporationMethod of increasing bone massUS46989172. Mai 198613. Okt. 1987Italvacuum Di Ing. P. Debolini & C. S.A.S.Rotary drier for drying heat-sensitive products and pharmaceuticalsUS470141721. Nov. 198520. Okt. 1987Boehringer Mannheim GmbhControl or calibration serum for lipid diagnosisUS47132494. Juli 198315. Dez. 1987Schroeder UlfCrystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereofUS47217094. Aug. 198426. Jan. 1988Pyare SethNovel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositionsUS47397546. Mai 198626. Apr. 1988Shaner William TSuction resistant inhalatorUS474187216. Mai 19863. Mai 1988The University Of Kentucky Research FoundationPreparation of biodegradable microspheres useful as carriers for macromoleculesUS47435541. Mai 198510. Mai 1988Boothroyd John CRecombinant DNA expression vector encoding for foot and mouth disease virus proteinsUS474957529. Jan. 19867. Juni 1988Bio-Dar Ltd.Microencapsulated medicament in sweet matrixUS475379016. Dez. 198628. Juni 1988Warner-Lambert CompanySorbitol coated comestible and method of preparationUS475858314. Nov. 198519. Juli 1988The Rockefeller UniversityMethod and agents for inhibiting protein agingUS47614006. Jan. 19862. Aug. 1988Jouveinal S.A.Laxative composition based on lactulose and its preparation processUS47627197. Aug. 19869. Aug. 1988Mark ForesterPowder filled cough productUS476285723. Apr. 19879. Aug. 1988E. I. Du Pont De Nemours And CompanyTrehalose as stabilizer and tableting excipientUS47780541. Dez. 198618. Okt. 1988Glaxo Group LimitedPack for administering medicaments to patientsUS479030523. Juni 198613. Dez. 1988The Johns Hopkins UniversityMedication delivery systemUS479082419. Juni 198713. Dez. 1988Bioject, Inc.Non-invasive hypodermic injection deviceUS479399729. Juni 198727. Dez. 1988Standard Telephone Cables Public Ltd. Co.Controlled delivery deviceUS481173129. Juli 198614. M�rz 1989Glaxo Group LimitedDevices for administering medicaments to patientsUS481244416. Dez. 198614. M�rz 1989Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoDehydration of hydrous matter using anhydrous glycosylfructoseUS48144368. Dez. 198621. M�rz 1989Ss Pharmaceutical Co., Ltd.Derivative of α, α-trehalose and a process for preparing the sameUS6290991 *2. Dez. 199418. Sept. 2001Quandrant Holdings Cambridge LimitedSolid dose delivery vehicle and methods of making sameEP0611567A1 *11. Juni 199324. Aug. 1994Teijin LimitedUltrafine powder for inhalation and production thereof* Vom Pr�fer zitiertNichtpatentzitateReferenz1Ablett, S., et al., (1992). "Differential Scanning Calorimetric Study Of Frozen Sucrose And Glycerol Solutions" J. Chem. Soc. Faraday Trans. 88(6):789-794.2Adjei, A. et al. (1994). "Pulmonary Delivery of Therapeutic Peptides and Proteins," J. Controlled Release 29:361-373.3Adler, M. et al., (2000). "Surface Composition of Spray-Dried Particles of Bovine Serum Albumin/Trehalose/Surfactant," Pharmaceutical Research 17(7):863-870.4Adler, M. et al., (Feb. 1999). "Stability and Surface Activity of Lactate Dehydrogenase in Spray-Dried Trehalose," Journal of Pharmaceutical Sciences, 88(2):199-208.5Agrimi, U. et al., (Feb. 1993) Med. Hypotheses 40(2):113-116.6Ahlneck, Claes and Zografi, George, The Molecular Basis of Moisture Effects on the Physical and Chemical Stability of Drugs in the Solid State, 62 Int's J. Pharm. 87-95 (1990).7Akers, M. J. et al., (1995). "Glycine Crystallization During Freezing: The Effects of Salt Form, pH, and Ionic Strength," Pharmaceutical Research 12(10):1457-1461.8Akers, M.J., et al., (Aug. 1994) "Top 10 current technical issues in parenteral science" Pharm. Tech. 18(8):26, 28, 30-33, 36.9Akoh et al. (1987) "One-stage synthesis of raffinose fatty acid polyesters" J. Food Sci. 52:1570-1576.10Albert, B. et al., Molecular Biology of the Cell, 2nd ed., Garland Publishing, Inc., Ch. 2, p. 58, (1989).11Aldous, B. J. et al. (1995). "The Crystallisation of Hydrates From Amorphous Carbohydrates," Cryo-Letters 16:181-186.12Aldrich, J. E. et al. (1974). "Use of the Spinning Disk Technique to Produce Monodisperse Microspheres of Human Serum Albumin for Labeling With Readioisotopes," The International Journal of. Applied Radiation and Isotopes 25:15-18.13Allen, D. J. et al., Determination of the Degree of Crystallinity in Solid-Solid Equilibria, J. Pharm. Sci. 58:1190-1193 (1969).14Allison, D. et al., (1999). "[Abstract] Preservation of Lipid/DNA Complexes During Acute Lyophilization Stress by Excipients in the Crystalline, Amorphous, and Rubber Phases,"1999 AAPS Annual Meeting, at http://www.aapspharmsci.org/abstracts/AM�1999/2095.htm, visited on Nov. 16, 2004, one page.15Allison, S. D. and Thomas J. Anchodorquy, Mechanisms of Protection of Cationic Lipid-DNA Complexes During Lyophilization, Journal of Pharmaceutical Sciences, 89(5):682-691 (May 2000).16Allison, S. D. et al. (2000). "Stabilization of Lipid/DNA Complexes During The Freezing Step Of The Lyophilization Process: The Particle Isolation Hypothesis," Biochimica et Biophysica Acta 1468:127-138.17Allison, S. D. et al., (Aug. 2001) "Lyophilization of Nonviral Gene Delivery Systems," Methods in Molecular Medicine, Series Methods in Molecular Medicine, vol. 65, pp. 225-252.18Allison, S. D. et al., (May 2000). "Mechanisms of Protection of Cationic Lipid-DNA Complexes During Lyophilization," Journal of Pharmaceutical Sciences 89(5):682-691.19Amal, A. et al., (20020. "Integrity of Crystalline Lysozyme Exceeds that of a Spray-Dried Form," International Journal of Pharmaceutics 247:79-90.20Anchordoquy T. et al. (1998). "Cryopreservation of Sperm from the Marine Shrimp Sicyonia ingentis," Cryobiology 25:238-243.21Anchordoquy, T. J. (2001). "Physical Stabilization of DNA-Based Therapeutics During Freezing and Drying," American Pharmaceutical Review 4(4):34-41.22Anchordoquy, T. J. et al. (1998). "[Abstract] Stabilization of Lipid/DNA Complexes During Acute Lyophilization and Rehydration Stress: A Comparison of Different Excipients," 1998 AAPS Annual Meeting, at http://www.aapspharmsci.org/abstracts/AM�1998/2520.html, visited on Nov. 16, 2004, one page.23Anchordoquy, T. J. et al. (May 2001). "Physical Stabilization of DNA-Based Therapeutics," Drug Discovery Today 6(9):463-470.24Anchordoquy, T. J. et al. (Sep. 1998). "Stability of Lipid/DNA Complexes during Agitation and Freeze-Thawing,"Journal of Pharmaceutical Sciences 87(9):1046-1051.25Anchordoquy, T.J. (2004). "Lyophilization and Storage Stability of Colloidal Gene Delivery Systems," Presentation given at conference regarding Freeze-Drying of Pharmaceuticals and Biologicals, Jul. 28-31, 2004, at http://www.ipph.purdue.edu/�nsf/freeze/presentations2004.html, visited on Nov. 10, 2004, 3 pages and PowerPoint� presentation of 32 pages, total of 35 pages.26Anchordoquy, T.J. et al. (Mar. 2000). "Physical Stability of Nonviral Plasmid-Based Therapeutics,"Journal of Pharmaceutical Sciences 89(3):289-296.27Anchordoquy, Thomas J. et al., Physical Stabilization of DNA Based Therapeutics, 6(9) DDT 463-470 (May 2001).28Andrews, A. T. (Aug. 1991). "Partial Denaturation and Renaturation of β-Lactoglobulin at Air-water Interfaces," Biochem Soc. Trans 19(3):272 S (one page).29Anekwe, J. U. et al., (1998). "Relaxation Constants as a Predictor of Protein Stabilization," Biocalorimetry: Applications of Calorimetry in the Biological Science, J. E. Ladbury, and B.Z. Chowdhry (eds.), John Wiley & Sons, 243-251.30Angell, C. A. (Mar. 21, 1995). "Formation of Glasses From Liquids and Biopolymers," Science 267:1924-1935.31Arakawa, T. et al., (1991). "Protein-Solvent Interactions in Pharmaceutical Formulations," Pharmaceutical Res. 8(3):285-291.32Bandara, G. et al., (Nov. 1993) "Interarticular Expression of Biologically Active Interleukin 1-Receptor-Antagonist Protein by Ex Vivo Gene Transfer," Proc. Natl. Acad. Sci.33Bandara, G. et al., (Nov. 1993) "Interarticular Expression of Biologically Active Interleukin 1-Receptor-Antagonist Protein by Ex Vivo Gene Transfer," Proc. Natl. Acad. Sci. 90:10764-10768.34Banker, G. S. et al. (eds), (1996). "Drug Absorption and Availability," Modern Pharmaceutics, 3rd edition, Marcel Dekker, Inc,. p. 145.35Barnett, A. H. (Apr. 2004). "Exhubera Inhaled Insulin: A Review," Int. J. Clin. Pract. 58(4):394-401.36Beaucage, S. L. et al. (1981). "Deoxynucleoside Phosphoramidites�A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," Tett. Lett. 22(20):1859-1862.37Bell, J. H. et al., Dry Powder Aerosols I: A New Powder Inhalation Device, 60(10) J. Pharm. Sci. 1559-1564 (Oct. 1971).38Belopol'skaya, T. V. et al., The Effect of Water as Natural Plasticizer on Thermal Properties of Denaturated DNA Studied by Calorimetry 4 Vestnik Sankt-Petersburgkogo Universiteta Seriya 16-22 (1999).39Bigsbee, D. R. (Oct. 1993). "Solid State Liability of Insulin: Comparison of Crystalline and Amorphous Forms," Pharmaceutical Research 10(10):Abstract No. PDD 7418, p. S-279.40Blakeley et al., (1990) "Dry instant blood typing plate for bedside use" Lancet 336:854-855.41Boehringer Ingelheim Notice of Opposition to European Publication No. 0773781B1, the European equivalent of U.S. Appl. No. 08/349,029 (to which the instant application claims priority), submitted Jul. 19, 2004, 21 pages.42B�gelein, J. et al., (2003). "Influence of Amorphous Mannitol on Powder Properties of Spray Dried Trehalose/Dextran Mixtures," at http://www.pharmtech.uni-erlangen.de/APV-03-abs/bogelein.pdf, visited on Sep. 2005, 2 pages.43B�gelein, J. et al., (2003). "Influence of Amorphous Mannitol on Powder Properties of Spray Dried Trehalose/Dextran Mixtures," at http://www.pharmtech.uni-erlangen.de/APV�03�abs/bogelein.pdf, visited on Sep. 2005, 2 pages.44Bone, S. et al., (1985). "Dielectric Studies of Protein Hydration and Hydration-Induced Flexibility," J. Mol. Biol. 181:323-326.45Bootsma, H. P. R. et al., (1989). "beta-Cyclodextrin as an Excipient in Solid Oral Dosage Forms: In Vitro and In Vivo Evaluation of Spray-Dried Diazepan-beta-Cyclodextrin Products," International Journal of Pharmaceutics 51:213-223.46Bootsma, H. P. R. et al., (1989). "β-Cyclodextrin as an Excipient in Solid Oral Dosage Forms: In Vitro and In Vivo Evaluation of Spray-Dried Diazepan-β-Cyclodextrin Products," International Journal of Pharmaceutics 51:213-223.47Bosquillon, C. et al., (2004). "Aerosolization Properties, Surface Composition and Physical State of Spray-Dried Protein Powders," Journal of Controlled Release 99:357-367.48Branca, C. et al., Destructuring effect of trehalose on the tetrahedral network of water: a Raman and neutron diffraction comparison, 304 Physica A 314-318(2002).49Branchu, S. et al., (1998). "The Effect of Cyclodextrins on Monomeric Protein Unfolding," Biocalorimetry: Applications of Calorimetry in the Biological Science, J. E. Ladbury and B.Z. Chowdhry, John Wiley &Sons, Ltd., 297-301.50Branchu, S. et al., (1999). "Hydroxypropyl-beta-Cyclodextrin Inhibits Spray-Drying-Induced Inactivation of beta-Galactosidase," Journal of Pharmaceutical Sciences 88(9):905-911.51Branchu, S. et al., (1999). "Hydroxypropyl-β-Cyclodextrin Inhibits Spray-Drying-Induced Inactivation of β-Galactosidase," Journal of Pharmaceutical Sciences 88(9):905-911.52Brange, J. et al., (1992). "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharmaceutical Research 9(6):715-726.53Breitenbach, J. (2002). "Melt Extrusion: From Process to Drug Delivery Technology," European Journal of Pharmaceutics and Biopharmaceutics 54:107-117.54Broadhead, J. et al., The Effect of Process and Formulation Variable on the Properties of Spray-Dried beta-Galactosidase, 46(6) J. Pharm. Pharmacol. 458-467 (Jun. 1994).55Broadhead, J. et al., The Effect of Process and Formulation Variable on the Properties of Spray-Dried β-Galactosidase, 46(6) J. Pharm. Pharmacol. 458-467 (Jun. 1994).56Broadhead, J. et al., The Spray Drying of Pharmaceuticals, 18 Drug Development and Industrial Pharmacy 1169-1206 (1992).57Brochure on Ready-to-Go� Molecular Biology Reagents: "PurePrep� Macro Plasmid Purification Kit," "Overview: Ready-to-Go� Technology," and "Ready-to-Go� Lambda Packaging Kit," by Pharmacia Biotech, Analects for Molecular and Cell Biology 22(2):1-7 (Spring 1994).58Brown, D. (Friday, Dec. 8, 1995). "Gene Therapy �Oversold� by Researchers, Journalists, NIH Advisers Cite Nearly Uniform Failure," Washington Post, A1, A22, Col. 1.59Brown, P. et al., (1990). "A Therapeutic Panorama of the Spongiform Encephalopaties," Antiviral Chem. Chemother. 1(2):75-84.60Buitink, Julia et al., High Critical Temperature above Tg May Contribute to the Stability of Biological Systems 79 Biophysical Journal 1119-1128 (Aug. 2000).61Burke, M. (1986). "Appendix D, The Glassy State and Survival of Anhydrous Biological Systems," in Membranes, Metabolism, and Dry Organisms, A. Carl Leopold, ed., Comstock Publishing Associates, pp. 358-363.62Burvall, A. et al., (1978). "Storage of Lactose-Hydrolised Dried Milk: Effect of Water Activity on the Protein Nutritional Value," Journal of Dairy Research 45:381-389.63Byron, Peter R. et al., Drug Carrier Selection�Important Physicochemical Characteristics Respiratory Drug Delivery, 5th Edition, Interpharm Press, 103-113 (1996).64Bystr�m, Katarina & Briggner, Lars-Erik, Microcalorimetry�A Novel Technique for Characterization of Powders, Respiratory Drug Delivery IV 297-302 (1994).65Carjaval, M. T. et al., (Oct. 1994). "Spray-Drying Optimization to Produce Powder for Inhalation," Pharmaceutical Research 11(10):S-140, Abstract No. PT6037.66Carpenter, J. et al., (1988). "Modes of Stabilization of a Protein by Organic Solute," Cryobiology 25:459-470.67Carpenter, J. F. et al. (1994). "Chapter 9: Interactions of Stabilizers With Protein During Freezing and Drying," ACS Symposium Series 567, Formulation and Delivery of Proteins and Peptides, J. L. Cleland & R. Langer (eds) 134-147.68Carpenter, J. F. et al., (1987). "Stabilization of Phosphofrucktokinase During Air-Drying with Sugars and Sugar/Transition Metal Mixtures," Cryobiology 24:455-464.69Carpenter, J.F., et al., (1988). "The Mechanism Of Cryoprotection Of Proteins By Solutes" Cryobiology 25:244-255.70Carpenter, John F. et al., Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice, 14:8 Pharmaceutical Res. 969-975 (1997).71Casselyn, M. et al., Time-Resolved Scattering Investigations of Brome Mosaic Virus Microcrystals Appearance D58 Acta Cryst. 1568-1570 (2002).72Caughey, B. et al., (1993). "Sulphated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells," J. Virol. 67(2):643-650.73Chan, H.-K. et al. (1997). "Spray Dried Powders and Powder Blends of Recombinant Human Deoxyribonuclease (rhDNase) for Aerosol Delivery," Pharmaceutical Research 14(4):431-437.74Chan, Hak-Kim and Gonda, Igor, Solid State Characterization of Spray-Dried Powders of Recombinant Human Deoxyribonuclease (RhDNase) 87(5) Journal of Pharmaceutical Sciences, 647-65 (May 1998).75Chan, Hak-Kim et al., Physical Stability of Salmon Calcitonin Spray-Dried Powders for Inhalation 93(3) Journal of Pharmaceutical Sciences 792-804 (Mar. 2004).76Chan, T. W. et al., (1988). "Formulation of Vaccine Adjuvant Muramyldipeptides (MDP). I. Characterization of Amorphous and Crystalline Forms of a Muramyldipeptide Analogue," Pharmaceutical Research 5(8):523-527.77Charm, S. E. et al., (Nov. 1970). "Enzyme Inactivation With Shearing," Biotechnol. Bioeng. 12:1103-1109.78Chavan, V. et al., (2000). "Effect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers," AAPS Pharmsci 2000; 2(2) article 10 at http://www.pharmsci.org, 7 pages.79Chavan, V. et al., (2002). "Novel System to Investigate the Effects of Inhaled Volume and Rates of Rise in Simulated Inspiratory Air Flow on Fine Particle Output From a Dry Powder Inhaler," AAPS Pharmasci 2002; 4(2) article 6 at http://www.aapspharmsci.org, 6 pages.80Chavan, V. S. et al., (1999). "Effect of Particle Size and Rise in Simulated Inspiratory Flow Rate on Device Emptying in a Dry Powder Inhaler System," at htpp://www.aapspharmsci.org/abstracts/AM�1999/1001.htm, visited on Jan. 7, 2005, 1 page.81Chawla, A. et al., (1994). "Production of Spray Dried Salbutamol Sulphate for Use in Dry Powder Aerosol Formulation," International Journal of Pharmaceutics 108:233-240.82Chiou et al., (Sep. 1971) "Pharmaceutical Applications of Solid Dispersion Systems" J. Pharm. 60(9):1281-1302.83Chiou, W. L. et al., (Sep. 1971). "Pharmaceutical Applications of Solid Dispersion Systems," Journal of Pharmaceutical Sciences 60(9):1281-1302.84Clark, A. R. et al. (1996). "The Balance Between Biochemical and Physical Stability For Inhalation Protein Powders: rhDNASE As An Example," Respiratory Drug Delivery V, pp. 167-174.85Clegg, J.S., (1985). "Chapter 10: The Physical Properties And Metabolic Status Of Artemia Cysts At Low Water Contents: The �Water Replacement Hypothesis�" Membranes, Metabolism and Dry Organisms, A. C. Leopold, ed., Comstock Publishing Associates, pp. 169-187.86Cleland, J. F. et al., (1993). "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation," Critical Reviews in Therapeutic Drug Carrier Systems, 10(4):307-377.87Cline, D. et al., (2002). "Predicting the Quality of Powders for Inhalation From Surface Energy and Area," Pharmaceutical Research 19(9):1274-1277.88Cline, D. et al., (2002). "Predicting the Quality of Powders for Inhalation," Respiratory Drug Delivery VIII 683-685.89Colaco, C. et al., (1992) "Trehalose Stabilization of Biological Molecules" Biotechnol. Internat. pp. 345-350.90Colaco, C. et al., (1993). Chemical Abstracts, vol. 118, 1992, No. 164103, CAPLUS on STN, one page.91Colaco, C. et al., (1994). "Chapter 14: Chemistry of Protein Stabilization by Trehalose," ACS Symposium Series 567, Formulation and Delivery of Proteins and Peptides, J. L. Cleland & R. Langer, pp. 222-240.92Colaco, C. et al., (Sep. 1992) "Extraordinary Stability of Enzymes Dried in Trehalose: Simplified Molecular Biology" Bio/Technology 10(9):1007-1011.93Colthorpe, P. et al., (1992). "The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheal and Aerosol Administration to the Rabbit," Pharmaceutical Research 9(6):764-768.94Considine, G. D. et al., (2002). Van Nostrand's Scientific Encyclopedia, 9th edition, vol. 2, Wiley-Interscience, John Wiley & Sons, Inc., Definition of Vaccines: pp. 3591-3592.95Costantino, H. R. et al., (1994). "Moisture-Induced Aggregation of Lyophilized Insulin," Pharmaceutical Research 11(1):21-29.96Costantino, H. R. et al., (Nov. 1998). "Effect of Mannitol Crystallization on the Stability and Aerosol Performance of a Spray-Dried Pharmaceutical Protein, Recombinant Humanized Anti-IgE Monoclonal Antibody," Journal of Pharmaceutical Sciences 87(11):1406-1411.97Craig, I. D. et al., (2001). "Maillard Reaction Kinetics in Model Preservation Systems in the Vicinity of the Glass Transition: Experiment and Theory," J. Agric. Food Chem. 49(10):4706-4711.98Crommelin, Daan, J. A. & Schreier, H. Liposomes J. Kreuter ed., Colloidal Drug Delivery Systems, Marcel Dekker, 73-190 (1994).99Crowe, J. H. et al., (1988). "Interactions of Sugars With Membranes," Biochimica et Biophysica Acta, 947:367-384.100Crowe, J. H. et al., (1990). "Are Freezing And Dehydration Similar Stress Vectors? A Comparison of Modes of Interaction of Stabilizing Solutes With Biomolecules" (1990) Cryobiol. 27:219-231.101Crowe, J.H., et al., (Apr. 1993). "Preserving Dry Biomaterials: The Water Replacement Hypothesis, Part 1" BioPharm 6(3):28-29, 32-33, 37.102Crowe, John H. et al., (1998). "The Role of Vitrification In Anhydrobiosis," Annu. Rev. Physiol. 60:73-103.103Crowe, John H. et al., (1998). "The Role of Vitrification in Anhydrobiosis," Annu. Rev. Physiol. 60:73-103.104Crowe, Lois M. et al. (Oct. 1996). "Is Trehalose Special for Preserving Dry Biomaterials?" Biophysical Journal 71:2087-2093.105Cynthia L. Stevenson, et al., (Sep. 2003). "Secondary Structure Of Cyclosporine Spray-Dried Liquid Crystal by FTIR", Journal of Pharmaceutical Sciences 92 (9):1832-1843.106Daemen, A. L. H. et al., (1982). "The Destruction of Enzymes and Bacteria During the Spray-Drying of Milk and Whey, 2. The Effect of the Drying Conditions," Neth. Milk Dairy J. 36:211-229.107Dalby, R. N. et al. (1992). "Droplets Drying and Electrostatic Collection a Novel Alternative to Conventional Comminution Techniques," Journal of Biopharmaceutical Sciences 3(�):091-099.108Dalby, R. N. et al., (2003). "Inhalation Therapy: Technological Milestones in Asthma Treatment," Advanced Drug Delivery 55:779-791.109Dalby, R. N. et al., (Oct. 1988). "Relationship Between Particles Morphology and Drug Release Properties After Hydration of Aerosols Properties After Hydration of Aerosols Containing Liposome Forming Ingredients," Pharmaceutical Research 5(10):S-94.110Darrington, R. T. et al., (Mar. 1995). "Evidence for a Common Intermediate in Insulin Deamidation and Covalent Dimer Formation: Effects of pH and Aniline Trapping in Dilute Acidic Solutions," Journal of Pharmaceutical Sciences 84(3):275-282.111D'Cruz, N. Relationship Between Protein Thermal Stability and Glass Transition in Gelatin-Polyol and Gelatin-Water Mixtures Proceedings of 2004 Meeting IFT, Jul. 12-16, 2004, Las Vegas, NV, Session 17E, Food Chemistry: Proteins, at http://ift.confex.com/ift/2004/techprogram/paper�23006.htm, 17-EA (2004).112De Carlo, S. et al., Unexpected Property of Trehalose as Observed by Cryo-Electron Microscopy 196(1) Journal of Microscopy 40-45 (Oct. 1999).113Dean Allison, S. & Anchordoquy, Thomas J., Lyophilization of Nonviral Gene Delivery Systems, 65 Methods in Molecular Medicine, Nonviral Vectors for Gene Therapy, Ch. 18, 225-252 (Mark A. Findeis ed., Humana Press, 2001).114Declaration of David Lechuga-Ballesteros, Ph.D. signed on Nov. 12, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 16 pages. (Exh: 1015).115Declaration of Geoffrey William James Lee, Ph.D. signed on Nov. 10, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 44 pages. (Exh: 2005).116Declaration of Richard Dalby, Ph.D. signed on Nov. 8, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 8 pages. (Exh:2046).117Declaration of Thomas Joseph Anchordoquy, Ph.D. signed on Nov. 11, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 13 pages. (Exh: 2041).118Derwent� WPI File 351, English Abstract of Japanese Application No. 82-98125 filed (Jun. 7, 1982).119Derwent� WPI File 351, English Abstract of PCT Publication No. WO 87/05300 (Sep. 11, 1987), also Japanese Publication No. 63-502592.120Development of a dry and thermostable oral polio vaccine, Progress Report QHCL and RIVM Nov. 1993-Apr. 1994, (Apr. 22, 1994), 11 pages total.121Development of a dry and thermostable oral polio vaccine, Progress Report QHCL, RIVM and RUG, May 1993-Oct. 1993, (Apr. 22, 1994), 9 pages total.122Development of a dry and thermostable oral polio vaccine, Progress Report QHCL, RIVM and RUG, May-Oct. 1993, (Apr. 22, 1994), 9 pages total.123D'Hondt, Eric Possible Approches to Develop Vaccines Against Hepatitis A, 10(Suppl. 1) Vaccine, S48, Abstract, lines 6-9 (1992).124Dialog� English Abstract of French Patent No. 2238476 (Mar. 28, 1975).125Dialog� English Abstract of Japanese Publication No. 58-216695 (Dec. 16, 1983), Japanese Patent Application No. 82-98125 filed Jun. 7, 1982.126Dialog� English Abstract of Japanese Publication No. 63-502592 (Sep. 29, 1988), Japanese Patent Application No. 87501509, national phase of PCT Publication No. WO 87/05300.127Dinnbier, U. et al., (1988). "Transient Accumulation Of Potassium Glutamate And Its Replacement By Trehalose During Adaptation Of Growing Cells Of Escherichia coli K-12 To Elevated Sodium Chloride Concentrations" Arch. Microbiol. 150:348-357.128Dorland's Illustrated Medical Dictionary, 26th ed., p. 666 (1985).129Dorland's Illustrated Medical Dictionary, 28th ed., pp. 36, 507, 1272, 1330 (1994).130Dorland's Illustrated Medical Dictionary, 28th Edition, W. B. Saunders Company, p. 1330, Definition of Polyol (1994).131Dose, K. et al. Survival in Extreme Dryness and DNA-Single-Strand Breaks 12(4) Advances in Space Research (4)221-(4)229 (1992).132During, M.J. et al., (Nov. 1994) "Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase," Science 266(5189):856-857.133Edwards, A. D. et al., (Aug. 20010. Crystallization of Pure Anhydrous Polymorphs of Carbamazepine by Solution Enhanced Dispersion With Supercritical Fluids (SEDS(TM)) Journal of Pharmaceutical Sciences 90(8):1115-1124.134Edwards, A. D. et al., (Aug. 20010. Crystallization of Pure Anhydrous Polymorphs of Carbamazepine by Solution Enhanced Dispersion With Supercritical Fluids (SEDS� ) Journal of Pharmaceutical Sciences 90(8):1115-1124.135Edwards, A. D. et al., (Aug. 20010. Crystallization of Pure Anhydrous Polymorphs of Carbamazepine by Solution Enhanced Dispersion With Supercritical Fluids (SEDS�) Journal of Pharmaceutical Sciences 90(8):1115-1124.136Eleutherio, E.C.A. et al., (1993). "Role of the Trehalose Carrier in Dehydration Resistence of Saccharomyces Cerevisiae," Biochimica et Biophysica Acta, 1156:263-266.137Elliott, R. B. et al., (1987). "Parenteral Absorption of Insulin From the Lung in Diabetic Children," Aust. Paediatr. J. 23:293-297.138Encyclopaedia Chimica, panel of Kagaku-Daijiten, Ed., vol. 7, pp. 310, 311 and English translation (1964).139Facsimile from Dr. D. L. Smith to Dr. B. Roser regarding product information of Stop'n Grow, (Jun. 26, 1997), 7 pages.140Fahy et al. (1984). "Vitrification as an Approach to Cryopreservation"Cryobiology 21:407-426.141Fakes, M. G. et al, (Apr. 2000). "Moisture Sorption Behavior of Selected Bulking Agents Used in Lyophilized Products," PDA J. Pharm Sci. Technol. 54(2):144-149, Abstract only at http://www.ncbi.nlm.nih.gov.142F�ldt, P. et al. (1994). "The Surface Composition of Spray-Dried Protein-Lactose Powders," Colloids and Surfaces A: Physiochemical and Engineering Aspects, 90:183-190.143Farhood, H. et al., (1992). "Effect of Cationic Cholesterol Derivatives on Gene Transfer and Protein Kinase C Activity," Biochimica et Biophysica Acta, 1111:239-246.144Felgner, P. L. et al., (Jan. 26, 1989). "Cationic Liposome-Mediated Transfection," Nature 337(6205): 387-388.145Final Office Action issued on Jul. 18, 2005, for U.S. Appl. No. 10/215,060, Paper No. 20050713, 9 pages total.146Finnar, I. L. (1996). "�14. Trehalose, m.p. 203� C," under "Carbohydrate", Organic Chemistry, vol. 2, Stereochemistry and the Chemistry of Natural Products, 5th edition, Longman, p. 323.147Finnar, I. L. (1996). "�14. Trehalose, m.p. 203� C.," under "Carbohydrate", Organic Chemistry, vol. 2, Stereochemistry and the Chemistry of Natural Products, 5th edition, Longman, p. 323.148Finney, J.S. et al, (1984). "Protein Hydration and Enzyme Activity: The Role of Hydration-Induced Conformation and Dynamic Changes in the Activity of Lysozyme," Comments on Molecular and Cellular Biophysics, Part A, 2(�):129-151.149Finot, P.A., et al., eds., (1990). The Maillard Reaction in Food Processing, Human Nutrition and Physiology, Birkh�user Verlag, Basel, title page and table of contents are included herewith, pp. 1-6.150Flink, J. M. (1983). "Chapter 17: Structure and Structure Transitions in Dried Carbohydrate Materials," in Physical Properties of Foods, M. Peleg and E.B. Bogley (editors), Aui Publishing, pp. 473-521.151Forbes, R. T. et al., (Nov. 1998). "Water Vapor Sorption Studies on the Physical Stability of a Series of Spray-Dried Protein/Sugar Powders for Inhalation," Journal of Pharmaceutical Sciences 87(11):1316-1321.152Fox, K. C. (Mar. 31, 1995). "Putting Proteins Under Glass," Science 267:1922-1923.153Franks, F. (1990). "Freeze Drying: From Empiricism to Predicatability," Cryo-Letters 11:93-110.154Franks, F. (1993). "Solid Aqueous Solutions," Pure & Appl. Chem. 65(12):2527-2537.155Franks, F. (Apr. 1994). "Accelarated Stability Testing of Bioproducts: Attractions and Pitfalls," TIBTECH 12:114-117.156Franks, F. (Feb. 1989). "Separation, Improved Freeze-Drying, An Analysis of the Basic Scientific Principles," Process Biochemistry 24(1):iii-vii.157Franks, F. (Oct. 1991). "Materials Science and the Production of Shelf-Stable Biologicals," Pharmaceutical Technological International 24:24-34.158Franks, F. et al. (1992). "Nucleation and Crystallization in Aqueous Systems During Drying: Theory and Practice," Pure & Appl. Chem. 64(11):1667-1672.159Franks, F., (Mar. 1994). "Long-Term Stabilization Of Biologicals" Bio/Tech. 12:253-256.160Franks, F., et al., (1993). "Stable Enzymes by Water Removal" in Stability and Stabilization of Enzymes, Proceedings of an International Symposium Held in Maastricht, The Netherlands, Nov. 22-25, 1992, van den Tweel, W.J.J., et al., eds., Elsevier, Amsterdam, pp. 45-54.161Franks, F., et al., (Oct. 1991). "Materials Science And The Production of Shelf-Stable Biologicals," BioPharm 4(9):38-55.162French, D. L. et al., (1995). "FTIR Investigation of Hydration-Induced Conformational Changes in Spray-Dried Protein, Trehalose Powders," Pharmaceutical Res. 12(9 Suppl.):S83, Abstract No. BIOTEC 2020.163French, D. L. et al., (1995). "Moisture Induced State Changes in Spray-Dried Trehalose/Protein Formulation," Pharmaceutical Res. 12(9 Suppl.):S83, Abstract No. BIOTEC 2019.164Friedmann, T. (Jun. 16, 1989). "Progress Toward Human Gene Therapy," Science 244(4910):1275-1281.165Fukuoka, E. et al. (1991). "Glassy State of Pharmaceuticals. V. Relaxation During Cooling and Heating of Glass by Differnetial Scanning Calorimetry," Chem. Pharm. Bull. 39(8):2087-2090.166G�nsslen, M. (1925). "On the Inhalation of Insulin," English translation including the original article "Uber Inhalation von Insulin" Klin. Wochenschr. 4:71 and attached article by Heubner et al., (1924). "Kurze Wissenschaftliche Mitteilungen," Klin. Wochenschrift 51:2342-2343.167Gennaro, A. R. ed. (1990). "Chapter 89 �Oral Solid Dosage Forms," In Remington's Pharmaceutical Science, 18th edition, Mack Publishing Co, Gennaro, A. R., pp. 1646-1647.168Gershon, H. et al., (1993). "Mode of Formation and Structural Features of DNA-Cationic Liposome Complexes Used for Transfection," Biochemistry 32:7143-7151.169Gi�ver, H. M. et al., (Jun. 1988). "Biochemical And Genetic Characterization Of Osmoregulatory Trehalose Synthesis In Escherichia coli" J. Bacteriol. 170(6):2841-2849.170Gibbs, J. H. et al., (Mar. 1958). "Nature of the Glass Transition and the Glassy State," The Journal of Chemical Physics 28(3):373-383.171Gilardi, P. et al., (Jul. 1990). "Expression of Human α-Antitrypsin Using a Recombinant Adenovirus Vector," FEBS 267(1):60-62.172Gold, V. et al., (1987). International Union of Pure and Applied Chemistry (IUPAC) Compendium of Chemical Terminology, 1st edition, Blackwell Scientific Publications, V. Gold et al., "Definition of Solid Solution And Mixed Crystal", p. 258 and p. 385.173Gorman, C. M. et al., (Nov. 1982). "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection," Proc. Natl. Acad. Sci. USA 79:6777-6781.174Govinda Rao, A. R. (1959). "Aerosol Insulin Inhalation Enquiry," Indian J. Physiol. Pharmacol. 3:161-167.175Graham, D. T. et al., (1984). "An In-Vitro Test for the Duration of Insulin Suspension," J. Pharm. Pharmacol. 36:427-430.176Green, J. L. et al., (1994). "The Protein-Glass Analogy: Some Insights from Homopeptide Comparisons," J. Phys. Chem. 98:13780-13790.177Green, J.L. et al., (1989). "Phase Relations and Vitrification in Saccharide-Water Solutions and the Trehalose Anomaly," J. Phys. Chem. 93:2880-2882.178Grounds of Decision for Opposition of Japanese Patent Application No. 63-505533, pp. 1-6 (Jul. 1996) with English translation.179Gupta, A. et al., (Mar. 15, 2004). "Single Virus Particle Mass Detection Using Microresonators With Nanoscale Thickness," Applied Physics Letters 84(11):1976-1978.180Habener, J. F. et al., (1971). "Parathyroid Hormone: Secretion and Metabolism In Vivo," Proc. Natl. Acad. Sci. USA 68(12):2986-2991.181Hahn, L. et al., (1989) "Solid Surfactant Solutions Of Active Ingredients In Sugar Esters," Pharmaceutical Research 6:958-960.182Hancock, B. C. et al. (1998). "A Pragmatic Test of Simple Calorimetric Method For Determining the Fragility of Some Amorphous Pharmaceutical Materials," Pharm. Res. 15(5):762-767.183Hancock, B. C. et al., (1993). "The Use of Solution Theories for Predicting Water Vapor Absorption by Amorphous Pharmaceutical Solids: A Test of The Flory-Huggins and Vrentas Models," Pharmaceutical Research 10(9):1262-1267.184Hancock, B. C. et al., (1994). "The Relationship Between the Glass Transition Temperature and the Water Content of Amorphous Pharmaceutical Solids," Pharmaceutical Research 11(4):471-477.185Hancock, B. C. et al., (1995). "Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures," Pharmaceutical Research 12(6):799-806.186Hancock, B. C. et al., (1999). "The Effect of Temperature on Water Vapor Sorption by Some Amorphous Pharmaceutical Sugars," Pharmaceutical Development and Technology 4(1):125-131.187Hancock, B. C. et al., (Jan. 1997). "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems," J. of Pharmaceutical Sciences 86(1):12.188Hancock, B. C. et al., (Oct. 1993). "The Relationship Between the Glass Transition Temperature and Water Content of Amorphous and Partially Amorphous Pharmaceutical Solids," Pharmaceutical Research, 10(10):p. S-279, Abstract No. PDD 7419.189Hanes, J. et al. (1997). "Porous Dry-Powder PLGA Microspheres Coated with Lung Surfactant for Systemic Insulin Delivery via the Lung," Proc. Int'l Symp. Control Rel. Bioactive Matter 24:57-58.190Harms, H. et al., (1987). "The Pulse Amplitude and Frequency Modulation of Parathyroid Hormone Secretion in Man," Int. Symp. On Osteoporosis, Aalborg, Abstract 232:723-724.191Harrington, C.R., et al., (1994). "A Glycation Connection" Nature 370:247-248.192Hastings, R. H. et al., (1992). "Clearance of Different-Sized Proteins From the Alveolar Space in Human and Rabbits," Journal of Applied Physiology, 73(4):1310-1316.193Hatley, R. H. M. (1991). "The Effective Use of Differential Scanning Calorimetry in the Optimisation of Freeze-Drying Processes and Formulations," Development Biol. Standard 74:105-122.194Hatley, R. H. M. et al., (1996). "Stabilization of Labile Materials by Amorphous Carbohydrates-Glass Fragility and the Physiochemical Properties that Make Trehalose a Superior Excipient," Pharmaceutical Research 13(9 Suppl.):S274.195Hawley's Condensed Chemical Dictionary, (1993). 12th Edition, Revised by J. Lewis, Sr., Von Nostrand Reinhold Company, pp. 16-17, 374, 938.196Health News Daily (Jan. 1995). "Pfizer and Inhale Therapeutic Systems Enter Pulmonary Insulin Collaboration for Dry Powder Aerosol Delivery," vol. 7, No. 13, pp. 4-5.197Heitefuss, R. et al., (1959). "The Stabilization of Extracts of Cabbage Leaf Proteins by Polyhydroxy Compounds for Electrophoretic and Immunological Studies," Archives of Biochemistry and Biophysics 85:200-208.198Heller, Martin C. et al., Protein Formulation and Lyophilization Cycle Design: Prevention of Damage Due to Freeze-Concentration Induced Phase Separation 63 Biotechnology & Bioengineering 166-174 (1999).199Herrington, D. L. (1934). "Some Physico-Chemical Properties of Lactose," J. Dairy Science 17:501-518.200Herrington, T. M. et al., (1984). "Physico-Chemical Studies on Sugar Glasses. I. Rates of Crystallization," Journal of Food Technology 19:409-425.201Hesch, R. D. et al., (1984). "First Clinical Observations with hPTH(1-38), a More Potent Human Parathyroid Hormone," Hormone Metabol. Res. 16(10):559-560.202Hesch, R. D. et al., (1988). "Pulsatile Secretion of Parathyroid Hormone and Its Action on a Type I and Type II PTH Receptor: A Hypothesis for Understanding Osteoporosis," Calcif. Tissue Int. 42:341-344.203Hickey, A. J. (1992). "Methods of Aerosol Particle Size Characterization," Chapter 8,Hicke y, ed. Pharmaceutical Inhalation Aerosol Technology, pp. 219-253.204Hickey, A. J. et al., (1993). "Behavior of Hygroscopic Pharmaceutical Aerosols and the Influence of Hydrophobic Additives," Pharmaceutical Research 10(1):1 -7.205Hodsman et al., (Jul. 1991). "Bone Densitometric and Histomorphometric Responses to Sequential Human Parathyroid Hormone (1-38) and Salmon Calcitonin in Osteoporotic Patients," Bone & Mineral 14(1):67-83.206Hodsman, A. B. et al., (May 1990). "Biochemical Responses to Sequential Human Parathyroid Hormone (1-38) and Calcitonin in Osteoporotic Patients," Bone & Mineral 9(2):137-152.207Hoener, Betty-Ann et al., (1996). "Factors Influencing Drug Absorption and Availability," Gilbert S. Banker et al. eds., Modern Pharmaceutics, Marcel Dekker Inc., Chapter 4, pp. 121-153.208Ibrahim, A. L. et al., (1983). "Spray Vaccination With an Improved F Newcastle Disease Vaccine. A Comparison of Efficacy With the B1 and La Sota Vaccines," Br. Vet. J. 139:213-219.209Igaki, N. et al., (1991). "The Inhibition of the Maillard Reaction by L Lysine In-Vitro," J. Jpn. Diabetes Soc. 34(5):403-407.210Iglesias et al. (1997). "Adsorption Isotherm of Amorphous Trehalose," J. Sci. Food Agric. 75:183-186.211Interview Summary issued for U.S. Appl. No. 11/134,573, mailed May 11, 2007, two pages.212Interview Summary issued for U.S. Appl. No. 11/134,700, mailed Feb. 27, 2007, two pages.213Israeli, E. et al., (1993). "Protection Of Freeze-Dried Escherichia coli By Trehalose Upon Exposure To Environmental Conditions," Cryobiol. 30:519-523.214Jameel, F. et al., (2001). "Freeze Drying Properties of Some Oligonucleotides," Pharmaceutical Development and Technology 6(2):151-157.215Japanese Document Regarding Opposition To Japanese Patent Application No. 63-505533 (English Translation Included), Abridged Translation Of Specification For PCT Patent Publication No. WO 87/00196, 1 page.216Jovanovic-Peterson, L. et al. (1993). "Jet-injected insulin is associated with decreased antibody production and postprandial glucose variability when compared with needle-injected insulin in gestational diabetic women," Diabetes Care 16(11):1479-1484.217Kachura, (1985). "Method of Drying Lactic Acid Bacteria," Vinodelie 1 Vinogradarstvo SSSR 2:49-50, English Abtract only, one page.218Kahn, R. et al., (1992). "Optimization of Retroviral Vector-Mediated Gene Transfer Into Endothelial Cells in Vitro," Circulation Research 71(6):1508-1517.219Kaneda, Y. et al., (Jan. 20, 1989). "Increased Expression of DNA Cointroduced With Nuclear Protein in Adult Rat Liver," Science 243:375-378.220Kanna, K. et al., (1974) "Denaturation of Fish Muscle Protein by Dehydration-V." Bull. Tokai Reg. Fish. Res. Lab. 77:1-17.221Kanna, K. et al., (1974) "Denaturation of Fish Muscle Protein by Dehydration�V." Bull. Tokai Reg. Fish. Res. Lab. 77:1-17.222Karel, M. (1975). "IV�Non-Equilibrium Situations in Water Sorption," and "V�Depression of Water Activity by Solutes," under Section 34 entitled "Physico-Chemical Modification of the State of Water in foods�A Speculative Survey," in Proceedings of an International Symposium on Water Relations of Foods held in Glasgow in Sep. 1974, edited by R. B. Duckworth, Academic Press, pp. 648-651.223Karmas, R. et al., (1992). "Effect of Glass Transition on Rates of Nonenzymatic Browning in Food Systems," J. Agric. Food Chem. 40:873-879.224Kauzmann, W. (1948). "The Nature of the Glassy State and the Behavior of Liquids at Low Temperatures," in Chemical Reviews, vol. 43, W. Albert Noyes, Jr. et al., eds., The American Chemical Society & The Williams & Wilkins Company, pp. 219-256.225Khan, R. (1984). "Chemistry And New Uses of Sucrose: How Important?" Pure & Appl. Chem. 56(7):833-844.226Khan, R. et al. (1990). "Cyclic Acetals of 4,1',6'-Trichloro-4,1',6'-Trideoxy-Galacto-Sucrose And Their Conversion Into Methyl Ether Derivatives," Carb. Res. 198:275-283.227Khan, R. et al. (1990). "Cyclic Acetals of 4,1′,6′-Trichloro-4,1′,6′-Trideoxy-Galacto-Sucrose And Their Conversion Into Methyl Ether Derivatives," Carb. Res. 198:275-283.228Khan, R. et al. (1993) "Enzymic Regioselective Hydrolysis Of Peracetylated Reducing Disaccharides, Specifically At The Anomeric Centre: Intermediates For The Synthesis Of Oligosaccharides," Tetra. Letts 34(48):7767-7770.229Klein, T. M. et al., (1987). "High Velocity Microprojectiles For Delivering Nucleic Acids Into Living Cells," Nature 327:70-73.230K�hler, D (1987). "Nicht Radioaktives Verfahren Zur Messung der Lungenpermeabilit�t: Inhalation von Insulin," Atemw Lungenkrkh 13:230-232, with English abstract.231K�hler, D. (1990). "Aerosols for Systemic Treatment," Lung. (Suppl.):677-684.232K�hler, D. (1993). "Systemic Therapy With Aerosol," in Aerosols in Medicine, Principles, Diagnosis, and Therapy, 2nd revised edition, edited by F. Mor�n et al., Elsevier Science Publishers B.V., pp. 303.233Labrude, P. et al., (1989). "Protective Effect of Sucrose on Spray Drying of Ocxyhemoglobin," Journal of Pharmaceutical Sciences, 78(3):223-229.234Labuza, T. et al., (Jan. 1992). "Glass Transition Temperatures of Food Systems," at http://faculty.che.umn.edu/fscn/Ted- Labuza/PDF-files/Isotherm- Folder/Tg%20compilation.pdf, visited on Sep. 2005.235Labuza, T. et al., (Jan. 1992). "Glass Transition Temperatures of Food Systems," at http://faculty.che.umn.edu/fscn/Ted� Labuza/PDF�files/Isotherm� Folder/Tg%20compilation.pdf, visited on Sep. 2005.236Lai, M. C. et al., (May 1999). "Solid-State Chemical Stability of Proteins and Peptides," Journal of Pharmaceutical Sciences 88(5):489-500.237Larsen, P. I. et al., (1987). "Osmoregulation In Escherichia coli By Accumulation Of Organic Osmolytes: Betaines, Glutamic Acid, And Trehalose," Arch. Microbiol. 147:1-7.238Laube, B. L. et al., (Oct. 2000). "Targeting Aerosol Deposition in Patients With Cystic Fibrosis, Effects of Alterations in Particle Size and Inspiratory Flow Rate," Chest 118(4):1069-1076.239Laube, B. L.et al. (Apr. 28, 1993). "Preliminary Study of the Efficacy of Insulin Aerosols Delivered by Oral Inhalation in Diabetic Patients," JAMA 269(16):2106-2109.240Lechuga-Ballesteros, D. (2003). "Administraci�n Sist�matica de Prote�nas en Polvos Inhalables," Informaceutico, 10(2):44, 46-47, in Spanish.241Lechuga-Ballesteros, D. et al. (Feb. 2003). "Microcalorimetric Measurement of the Interactions between Water Vapor and Amorphous Pharmaceutical Solids", Pharmaceutical Research, 20(2):308-318. Chosen as a highlight of the Pharm. Res. February issue in the AAPS Newsmagazine vol. 6 No. 2.242Lechuga-Ballesteros, D. et al., (2000). "Aerosol Drug Development Of A Spray Dried Liquid Crystalline Formulation Of Cyclosporine", Respiratory Drug Delivery VII, Serentec Press, Inc. Raleigh, North Carolina, pp. 247-255.243Lechuga-Ballesteros, D. et al., (2002). "Residual Water In Amorphous Solids, Measurement And Effect On Stability" in Amorphous Food and Pharmaceutical Systems, H. Levine, (Ed.) The Royal Society of Chemistry, London, pp. 275-316.244Lechuga-Ballesteros, D. et al., (Sep. 2003). "Properties and Stability of a Liquid Crystal Form of Cyclosporine�The First Reported Naturally Occurring Peptide That Exists as a Thermotropic Liquid Crystal", Journal of Pharmaceutical Sciences, 92 (9):1821-1831.245Ledl, F., et al., (Jun. 1990). "New Aspects Of The Maillard Reaction In Foods And In The Human Body," Ang. Chem. Int. Ed. Engl. 29:565-594.246Lee, C. K. (1980). Developments in Food Carbohydrate-2nd edition Applied Science Publishers, London, Table of Contents, 4 pages.247Lee, C. K. (1980). Developments in Food Carbohydrate�2nd edition Applied Science Publishers, London, Table of Contents, 4 pages.248Lee, G. (2002). "Chapter 6: Spray Drying of Proteins," in Rational Design of Stable Protein Formulations, Theory and Practice, J. F. Carpenter & M. Manning, pp. 1-39.249Lee, G. et al., (Jan. 1996). "Stabilisierung von Peptidarzneistoffen durch Gefriertrocknung," Prisma, 3(2):105-116.250Lee, G. et al., (May 1985). "Rheological Properties of Non-Modified and n-Alkyl Surface-Modified Colloidal Silica Sols," Journal of Colloid and Interface Science, 105(1):257-266.251Lee, S.-W. et al. (Apr. 1976). "Development of an Aerosol Dosage Form Containing Insulin," J. Pharmaceutical Sci.65(4):567-572.252Lehninger, Albert L. The Molecular Basis of Cell Structure and Function Biochemistry, Chapter 31, 859-890 (Worth Publishers Inc., 2nd edition, 1975).253Leslie, S. B. et al., (Oct. 1995). "Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying" Appl. Env. Microbiol. 61(10):3592-3597.254Leuner, C. et al. (2000). "Improving Drug Solubility for Oral Delivery Using Solid Dispersions," European Journal of Pharmaceutics and Biopharmaceutics 50:47-60.255Levine, H. et al., (1986). "A Polymer Physico-Chemical Approach to the Study of Commercial Starch Hydrolysis Products (SHPs)," Carbohydrate Polymers 6:213-244.256Levine, H. et al., (1988). "Chapter 9: Collapse Phenomena�A Unifying Concept For Interpreting The Behaviour of Low Moisture Foods," in Food Structure�Its Creation and Evaluation, J.M. Blanshard et al., (editors), pp. 149.180.257Levine, H. et al., (1988). "Principles of �Cryostabilization� Technology from Structure/Property Relationships of Carbohydrate/Water Systems, A Review," Cryo-Letters 9:21-63.258Levine, Harry & Slade, Louise (May 1992). "Another View of Trehalose for Drying and Stabilizing Biological Materials," Biopharm 5:36-40.259Li, Z. et al., (2002). "Realistic In Vitro Assessment of Dry Powder Inhalers," Respiratory Drug Delivery VIII, pp. 687-689.260Lin, S.-Y. et al., (1989). "Solid Particles of Drug-beta-Cyclodextrin Inclusion Complexes Directly Prepared by a Spray-Drying Technique," Internation Journal of Pharmaceutics, 56:249-259.261Lin, S.-Y. et al., (1989). "Solid Particles of Drug-β-Cyclodextrin Inclusion Complexes Directly Prepared by a Spray-Drying Technique," Internation Journal of Pharmaceutics, 56:249-259.262Lindberg, J. (1993) "Creating the Future for Portable Inhalers," Summary of Lecture at Management Forum Dec. 6-7, 1993, 2 pages total.263Liu, Jinsong et al., (Aug. 2002). "Dynamics of Pharmaceutical Amorphous Solids: The Study of Enthalpy Relaxation by Isothermal Microcalorimetry," Journal of Pharmaceutical Sciences 91(8):1853-1862.264Louey, M. D. et al., (2004). "Controlled Release Products for Respiratory Delivery," This article was published in the Jul./Aug. 2004 issue of APR, vol. 7, Issue 4, on pp. 82-87, at http://www.americanpharmaceuticalreview.com/article.aspx?article=77, visited on Sep. 2005, 11 pages.265Louis, P. et al., (1994). "Survival Of Escherichia coli During Drying And Storage In The Presence Of Compatible Solutes" Appl. Microbiol. Biotechnol. 41:684-688.266Lueckel, B. et al., (1998). "Effects of Formulation and Process Variables on the Aggregation of Freeze-Dried Interleukin-6 (IL-6) After Lyophilization and on Storage," Pharmaceutical Development and Technology 3(3):337-346.267Maa, Y.-F. et al., (1997). "The Effect of Operating and Formulation Variables on the Morphology of Spray-Dried Protein Particles," Pharmaceutical Development and Technology 2(3):213-223.268MacKenzie, A.P. (1975) Collapse During Freeze Drying�Qualitative and Quantitative Aspects Freeze Drying and Advanced Food Technology, Academic Press, London, Chapter 19, pp. 277-307.269Makower, B. & W. Dye, (Jan. 1956) "Equilibrium Moisture Content and Crystallization of Amorphous Sucrose and Glucose, "Agric. and Food Chem. 4(1):72-77.270Makower, B. & W. Dye, (Jan. 1956) "Equilibrium Moisture Content and Crystallization of Amorphous Sucrose and Glucose," Agric. and Food Chem. 4(1):72-77.271Malcolm, W. et al. (1955). "The Temperature Dependence of Relaxation Mechanisms in Amorphous Polymers and Other Glass-Forming Liquids," Temperature Dependence of Relaxation Mechanisms 77:3701-3707.272Martin, A. et al., States of Matter and Phase Equilibria Physical Pharmacy, Physical Chemical Principles in the Pharmaceutical Sciences, 3rd. ed., Chapter 4, 62-91 (1983).273Masters, K. (1991). "Chapter 16 �Applications in the Pharmaceutical �Biochemical Industry," In Spray Drying Handbook, 5th edition, Longman Scientific & Technical and John Wiley & Sons, Inc., pp. 643-662.274Masters, K. (1991). "Chapter 2 �Representation of Sprays," In Spray Drying Handbook, 5th edition, Longman Scientific & Technical and John Wiley & Sons, Inc., pp. 67-69.275Masters, K. (1991). "Chapter 8 �Drying of Droplets/Sprays," In Spray Drying Handbook, 5th edition, Longman Scientific & Technical and John Wiley & Sons, Inc., pp. 309-352.276Masters, K. (1991). "Introduction," In Spray Drying Handbook, 5th edition, Longman Scientific & Technical and John Wiley & Sons, Inc., pp. 1-9 with Table of Contents.277Masters, K. (1991). "Part I �Basic Principles, Definitions �1 Spray Drying Fundamentals: Process Stages," In Spray Drying Handbook, 5th edition, Longman Scientific & Technical and John Wiley & Sons, Inc., pp. 32-33.278Masters, K. Spray Drying Handbook, England; Longman Scientific & Technical, 5th ed., Chapters 13 and 15. (1991).279Masters, K. Spray Drying Handbook, England; Longman Scientific & Technical, 5th ed., pp. 640-642(1991).280Matsuda, Y. et al., (Nov. 7, 1991). "Amorphism and Physicochemical Stability of Spray-Dried Frusemide," J. Pharm. Pharmacol. 44:627-633.281Mattern, Markus et al., Formulation of Proteins in Vacuum�Dried Glasses. II. Process and Storage Stability in Sugar-Free Amino Acid Systems 4(2) Pharmaceutical Development & Technology 199-208 (1999).282McGraw-Hill Encyclopedia of Science & Technology, 6th ed., vol. Nos. 7, 12, 14, pp. 637, 395, and 405 (1987).283Meisner, D. et al. (Oct. 1994). "Evaluation of a New Breath-Actuated Dry Powder Inhaler Prototype," Pharmaceutical Research 11(10):S140, Abstract No. PT6038.284Merriam Webster's Collegiate Dictionary, 10th ed. 568, 717 (1994).285Merriam Webster's Collegiate Dictionary, 10th ed., 335 (1994).286Merriam Webster's Collegiate Dictionary, 346, 1119, (10th ed. 1994).287Merriam Webster's Collegiate Dictionary, Merriam-Webster, Incorporated, Springfield, Massachusetts, USA, 10th edition, p. 334 (2002).288Merriam Webster's Third International Dictionary, 433 (1993).289Michelson, J. (1976). "Chapter 22: Pilot Plant Scale-Up Techniques," in The Theory and Practice of Industrial Pharmacy, 2nd edition, Lega & Febiger, pp. 626-649.290Miller, D. P. et al., (1998). "Stabilization of Lactate Dehydrogenase Following Freeze-Thawing and Vacuum-Drying in the Presence of Trehalose and Borate," Pharmaceutical Research 15(8):1215-1221.291Molina, M. C. et al., (Sep. 2004). "The Stability of Lyophilized Lipid/DNA Complexes During Prolonged Storage," J. Pharm. Sci. 93(9):2259-2273, abstract only, one page, at http://www.ncbi.nlm.nih.gov, visited on Sep. 2005.292Monnier et al., Mechanisms of Protection Against Damage Mediated by the Maillard Reaction in Aging Gerontology 37:152-165 (1991).293Mouradian, R. et al., (1985). "Degradation of Functional Integrity During Long-Term Storage of a Freeze-Dried Biological Membrane," Cryobiology 22:119-127.294Mouradian, R. et al., (1985). Degradation of Functional Integrity During Long-Term Storage of.295Moynihan, C. T. et al. (1974). "Dependence of the Glass Transition Temperature on Heating and Cooling Rate," J. Physical. Chem. 78(26):2673-2677.296Mumenthaler, M. et al., (1994). "Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator," Clinical Research 11(1):12-20.297Mumenthaler, M. et al., (May 27, 1991). "Atmospheric Spray-Freeze Drying: A Suitable Alternative in Freeze-Drying Technology," International Journal of Pharmaceutics 72(2):97-110.298Murphy, B. R. et al., (1990). "Chapter 19: Immunization Against Viruses," in Fields of Virology, 2nd edition, vol. 1, Raven Press, pp. 469-502.299Murphy, Brian R. and Chanock, Robert M. Fields Virology, vol. 1, Chapter 16 entitled Immunization Against Virus Disease, 467, at p. 468, first full paragraph, first column, lines 26-33 (Bernard N. Fields et al. eds., Lippincott-Raven Publishers, 3rd ed. 1996).300Nabel, G. J. et al., (Dec. 1993) "Direct Gene Transfer With DNA-Liposome Complexes in Melanoma," Proc. Natl. Acad. Sci. 90:11307-11311.301Nabel, G. J. et al., "Immunotherapy of Malignancy by In Vivo Gene Transfer Into Tumors," Hum. Gene. Ther. 3(4):399-410 (Aug. 1992).302Nagai, T. (1984). "Powder Dosage Form of Insulin for Nasal Administration," Journal of Controlled Release, pp. 15-22, see abstract, Tables and discussion.303Nagano, M. et al., (1985). "New Method of Insulin Therapy: Transpulmonary Absorption of Insulin,"Jikeikai Med. J. 32:503-506.304Naini, V. et al., (1994). "Physical Characterization of Spray Dried Sugars Suitable as Carriers in Inhalation Systems," Presented at a poster at 10th Annual AAPS, Miami, Florida, PT6180, 14 pages.305Naini, V. et al., (1996). "Particles for Inhalation Produced by Spray Drying and Electrostatic Precipitation of Different Protein-Sugar Solutions," Respiratory Drug Delivery V, pp. 382-384.306Naini, V. et al., (1998). "Physicochemical Stability of Crystalline Sugars and Their Spray-Dried Forms: Dependence Upon Relative Humidity and Suitability for Use in Powder Inhalers," Drug Development and Industrial Pharmacy 24(10):895-909.307Naini, V. et al., (Sep. 1995). "Physical Characterization of Spray Dried Sugars Suitable as Carriers in Inhalation Systems," Pharmaceutical Research 12(9):S181, Abstract No. PT6180.308Natarajan, Padmaja (Jan. 3, 2002), Crystallization Conditions for VIPER Entries at http://www.xtal.tsinghua.edu.cn/research/group5/web/material/Virus%20Crystallization%20Page.htm visited on Nov. 4, 2004, 5 pages (last updated Jan. 3, 2002).309Neer, R. M. et al., (1987). "The Use of Parathyroid Hormone Plus 1,25-Dihydroxyvitamin D to Increase Trabecular Bone in Osteoporotic Men and Postmenopausal Women," Osteoporosis 53:829-835.310Nektar Motion No. 2 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 109 pages.311Nektar Motion No. 3 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 94 pages.312Nektar Motion No. 4 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 112 pages.313Nektar Motion No. 5 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 59 pages.314Nektar Motion No. 6 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 63 pages.315Nektar Motion No. 7 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 114 pages.316Nektar Motion No. 8 filed on Dec. 10, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 25 pages.317Nektar Motion No. 9 filed on Dec. 10, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 24 pages.318Nektar Notice of Opposition to European Publication No. 0773781B1, the European equivalent of U.S. Appl. No. 08/349,029 (to which the instant application claims priority), submitted Jul. 22, 2004, 17 pages.319Nektar Opposition to Quadrant Preliminary Motion No. 7 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 30 pages.320Nektar Opposition to Quadrant Responsive Motion No. 1 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 35 pages.321Nektar Opposition to Quadrant Substantive Motion No. 1 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 33 pages.322Nektar Opposition to Quadrant Substantive Motion No. 2 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 30 pages.323Nektar Opposition to Quadrant Substantive Motion No. 3 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 28 pages.324Nektar Opposition to Quadrant Substantive Motion No. 4 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 29 pages.325Nektar Opposition to Quadrant Substantive Motion No. 5 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 30 pages.326Nektar Opposition to Quadrant Substantive Motion No. 6 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 18 pages.327Nektar Opposition to Quadrant Substantive Motion No. 8 filed on Feb. 4, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 16 pages.328Nektar Reply in Support Of its Motion No. 2 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 20 pages.329Nektar Reply In Support Of its Motion No. 3 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 20 pages.330Nektar Reply In Support Of its Motion No. 4 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent Bo. 6,290,991 (Roser et al.), to which the instant application claims priority, 17 pages.331Nektar Reply in Support Of its Motion No. 5 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 14 pages.332Nektar Reply In Support Of its Motion No. 6 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 14 pages.333Nektar Reply In Support Of its Motion No. 7 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 20 pages.334Nektar Reply In Support Of its Motion No. 8 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 14 pages.335Nektar Reply In Support Of its Motion No. 9 filed on Mar. 11, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 27 pages.336Nektar Therapeutics' Request for Interference Pursuant to 37 C.F.R. � 1.607, mailed Jan. 8, 2004, from the prosecution history of Nektar U.S. Appl. No. 10/245,722, filed Sep. 18, 2002 (published as U.S. Publication No. 2003/0092666).337Nektar U.S. Appl. No. 08/044,358 filed Apr. 7, 1993, Paper No. 5, Amendment dated Feb. 23, 1994 (Abandoned).338Nektar U.S. Appl. No. 08/044,358, "Compositions and Methods For Nucleic Acid Delivery To The Lung" filed by Patton et al. on Apr. 7, 1993, assigned to Inhale Therapeutic Systems.339Nektar U.S. Appl. No. 08/417,507 filed Apr. 4, 1995, with the File Wrapper Continuation's Request.340Nektar U.S. Appl. No. 08/422,563 filed Apr. 14, 1995.341Nektar U.S. Appl. No. 08/422,563, filed Apr. 14, 1995, Paper No. 16, Response under 37 C.R.F. � 1.129, mailed Feb. 5, 1998 (Patent No. 5,994,314).342Nektar U.S. Appl. No. 08/422,563, filed Apr. 14, 1995, Paper No. 17, Office Communication mailed Apr. 3, 1998 (Patent No. 5,994,314).343Nektar U.S. Appl. No. 08/422,563, filed Apr. 14, 1995, Paper No. 8, Amendment, mailed Dec. 10, 1996 (Patent No. 5,994,314).344Nektar U.S. Appl. No. 10/245,706, filed Sep. 18, 2002, Non-Final Office Action, Paper No. 6, mailed Feb. 26, 2003.345Nektar U.S. Appl. No. 10/245,706, filed Sep. 18, 2002, Reply to Office Action, mailed on May 27, 2003.346Nektar U.S. Appl. No. 10/245,722, Preliminary Amendment, Paper No. 4, mailed Sep. 18, 2002 from the prosecution history of U.S. Appl. No. 10/245,722, Pub. No. US 2003/0092666 ("the '722 Application"), filed Sep. 18, 2002, (the Application-in-Interference).347Nektar's U.S. Appl. No. 08/207,472, filed Mar. 7, 1994, abandoned.348Nektar's U.S. Appl. No. 08/246,034, filed May 18, 1994.349Nektar's U.S. Appl. No. 10/245,722, filed Sep. 18, 2002.350New Shorter Oxford English Dictionary on Historical Principles, 1993, p. 68, definition of amorphous.351New Shorter Oxford English Dictionary on History Principles, Lesley Brown ed., Clarendon Press Oxford, p. 3592, Definition of "Vitreous" (1993).352Niven, R. W. (19950. "Delivery of Biotherapeutics by Inhalation Aerosol," Critical Reviews in Therapeutic Drug Carrier Systems, 12(2&3):151-231.353Niven, R. W. (Jul. 1993). "Delivery of Biotherapeutics by Inhalation Aerosols," Pharmaceutical Technology 72:73-74, 80.354Non Final Office Action issued on Aug. 1, 2005, for U.S. Appl. No. 10/857,100, Paper No. 07222005, 6 pages total.355Non Final Office Action issued on Dec. 2, 2004, for U.S. Appl. No. 10/215,060, Paper No. 20041201, with PTO-Form 892, 10 pages total.356Non Final Office Action issued on Dec. 8, 2004, for U.S. Appl. No. 10/857,100, Paper No. 11262004, with PTO-Form 892, 8 pages total.357Non Final Office Action issued on Jul. 14, 2004, for U.S. Appl. No. 10/652,212, Paper No. 07082004, with PTO-Form 892, 6 pages total.358Norberg, J. et al., (Sep. 1996). "Glass Transition in DNA From Molecular Dynamics Simulation," Proc. Natl. Acad. Sci. USA 93:10173-10176.359Notice of Allowance, Notice of Allowability, Examiner's Amendment and Examiner-Initiated Interview Summary issued for U.S. Appl. No. 10/652,212, mailed Aug. 12, 2005, eight pages.360Nursten, H.E., (1986). "Maillard Browning Reactions In Dried Foods" in Concentration and Drying of Foods, McCarthy, D. ed., Elsevier Applied Science, London, pp. 53-68.361O'Connor, R. E. (1990). "Powders," in Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, ed., Mack Publishing Co. Chapter 88, pp. 1615-1632.362Odegard, P. S. et al., (May 2005). "Inhaled Insulin: Exubera," The Annals of Pharmacotherapy39:843-853.363Office Action issued for U.S. Appl. No. 10/652,212, mailed Jul. 14, 2004, 5 pages.364Office Action issued for U.S. Appl. No. 10/857,100, mailed Apr. 11, 2006, 11 pages.365Office Action issued for U.S. Appl. No. 10/857,100, mailed Aug. 1, 2005, 8 pages.366Office Action issued for U.S. Appl. No. 10/857,100, mailed Dec. 8, 2004, 7 pages.367Office Action issued for U.S. Appl. No. 10/857,100, mailed Sep. 20, 2006, 6 pages.368Office Action issued for U.S. Appl. No. 11/134,573, mailed Dec. 15, 2005, five pages.369Office Action issued for U.S. Appl. No. 11/134,573, mailed Mar. 13, 2007, nine pages.370Office Action issued for U.S. Appl. No. 11/134,573, mailed Sep. 6, 2006, 10 pages.371Office Action issued for U.S. Appl. No. 11/134,700, mailed Jan. 17, 2006, 6 pages.372Office Action issued for U.S. Appl. No. 11/134,700, mailed May 29, 2007, 8 pages.373Office Action issued for U.S. Appl. No. 11/134,700, mailed Sep. 26, 2006, 11 pages.374Ohtake, S. et al., (Sep. 20040. "Effect of pH, Counter Ion and Phosphate Concentration on the Glass Transition Temperature of Freeze-Dried Sugar-Phosphate Mixtures," Pharmaceutical Research 21(9):1615-1621.375Okamoto, H. et al., (20020. "Dry Powders for Pulmonary Delivery of Peptides and Proteins," Kona No. 20:71-83.376Oksanen, C. A. et al., (1990). "The Relationship Between the Glass Transition Temperature and Water Vapor Absorption by Poly(Vinylpyrrolidone)," Pharmaceutical Research 7(6):654-657, and errata on p. 974.377Okumura, K. et al., (Jan. Feb. 1994). "Intratracheal Delivery of Calcitonin Dry Powder in Rats and Human Volunteers," S.T.P. Pharmaceutical Sciences 4(1):5 pages.378Onodera, et al. (1968). "Glass Transition of Dehydrated Amorphous Solid," Bull. Chem. Soc. Japan 41(9):2222.379Owens, D. R. et al., (20030. "Alternative Routes of Insulin Delivery," Diabetic Medicine 20:886-898.380Palmer, K. J. et al. (Jan. 1956). "X-Ray Diffractometer and Microscopic Investigation of Crystallization of Amorphous Sucrose," Agricultural and Food Chemistry 4(1):76-81.381Parks et al. (1928). "Studies on Glass. II The Transition Between the Glassy and Liquid States in the Case of Glucose," Journal of Physical Chemistry 1366-1379.382Patel, M. M. et al., (Oct. 2004). "Degradation Kinetics of High Molecular Weight Poly(L-Lactide) Microspheres and Release Mechanism of Lipid: DNA Complexes," Journal of Pharmaceutical Sciences, 93(10):2573-2584.383Patton, J. S. (1993). "Chapter 16: Alternatives to Injections: Pulmonary Delivery of Peptides and Proteins," in Therapeutic Proteins Pharmacokinetics and Pharmacodynamics, King, et al., (eds), pp. 329-347.384Patton, J. S. (Oct. 1998). "Deep-Lung Delivery of Proteins," Modern Drug Discovery pp. 19-28.385Patton, J. S. et al. (1994). "Bioavailability of Pulmonary Delivered Peptides and Proteins,: α-Interferon, Calcitonins and Parathyroid Hormones," J. Controlled Release 28:79-85.386Patton, J. S. et al., (1992). "Routes of Delivery: Case Studies, Pulmonary Delivery of Peptides and Proteins for Systemic Action," Adv. Drug Delivery Reviews 8:179-196.387Pearlman et al. "Formulation Strategies for Recombinant Proteins: Human Growth Hormone and Tissue Plasminogen Activator," in Therapeutic Peptids and Proteins, Formulation, Delivery and Targetting, Cold Spring Harbour, New York, pp. 23-31.388Pearlman, R. et al. (Feb. 1992). "Pharmaceutics of Protein Drugs," J. Pharm. Pharmacol. 44(Suppl. 1):178-185.389Pekarek et al. (1994) "Double-walled polymer microspheres for controlled drug release" Nature 367:258-260.390Phillips, E. et al., (1998). "Size Reduction of Peptides and Proteins by Jet-Milling," Respiratory Drug Delivery VI, pp. 161-167.391Pikal, M. J. (Oct. 1990). "Freeze-Drying of Proteins Part II: Formulation Selection," Biopharm 3(8):26-30.392Pikal, M. J. (Sep. 1995). "Modulated DSC Studies," Pharmaceutical Research 12(9):S-139, Abtract No. PT 6011.393Pikal, M. J. et al. (1977). "Thermal Decomposition of Amorphous Beta Lacam Antibacterials," Journal of Pharmaceutical Science 66:1312-1316.394Pikal, M. J. et al., (1990). "Moisture Transfer from Stopper to Product and Resulting Stability Implications," International Symposium on Biological Product Freeze-Drying and Formulation, Bethesda, USA, in Developments in Biological Standardization, (International Association of Biological Standardization, J. C. May and F. Brown, Acting Ed.) 74:165-179.395Pikal, M. J. et al., (1997). "The Stability of Insulin in Crystalline and Amorphous Solids: Observation of Greater Stability for the Amorphous Form," Pharmaceutical Research 14(10):1379-1387.396Pikal, M. J. et al., (1998). Errata of "The Stability of Insulin in Crystalline and Amorphous Solids: Observation of Greater Stability for the Amorphous Form," Pharmaceutical Research 15(2):362-363.397Pikal, M.J., (Sep. 1990). "Freeze-Drying of Proteins. Part I: Process Design" BioPharm 3(8):18-20, 22-23, 26-27.398Pine, S. H. et al., (1980). "15-3 Oligosaccharides and Polysaccharides," Organic Chemistry, 4th edition, McGraw-Hill International Book Company, p. 763.399Pisecky, J. (1997). "2. Evaporation and Membrane Filtration," in Handbook of Milk Powder Manufacture, Niro A/S, Denmark, p. 3.400Pocchiari, M. et al. (1989). "Amphotericin B: A Novel Class of Antiscrapie Drugs," J. Infect. Dis. 160(5):795-802.401Poole, P.L. et al., (1983). "Hydration-Induced Conformational and Flexibility Changes Inlysozyme at Low Water Content," Int. J. Biol. Macromol. 5:308-310.402Poole, P.L. et al., (1983). "Sequential Hydration of a Dry Globular Protein," Biopolymers 22:255-260.403Potts, M. (1994). "Desiccation Tolerance of Prokaryotes," Micro. Rev. 58(4):755-805.404Preliminary Amendment, Paper No. 4, mailed Sep. 18, 2002 from the prosecution history of U.S. Appl. No. 10/245,722, Pub. No. US 2003/0092666 ("the '722 Application"), filed Sep. 18, 2002, (the Application-in-Interference).405Prestrelski, S. J. et al., (1995). "Optimization of Lyophilization Conditions for Recombinant Human Interleukin-2 by Dried-State Conformational Analysis Using Fourrier-Transform Infrared Spectroscopy," Pharmaceutical Research 12(9):1250-1259.406Prestrelski, S. J. et al., (Jun. 1993). "Separation of Freezing and Drying-Induced Denaturation of Lyophilized Proteins Using Stress-Specific Stabilization," Archives of Biochemistry and Biophysics 303(2):465-473.407Quadrant Drug Delivery Ltd. v. Nektar Therapeutics Interference No. 105,219, Paper No. 1 in Patent Interference No. 105,219 mailed Jun. 9, 2004, Notice Declaring Interference.408Quadrant Motion No. 1 on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 28 pages.409Quadrant Motion No. 2 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 30 pages.410Quadrant Motion No. 3 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 18 pages.411Quadrant Motion No. 4 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 30 pages.412Quadrant Motion No. 5 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 53 pages.413Quadrant Motion No. 6 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 16 pages.414Quadrant Motion No. 7 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 92 pages.415Quadrant Motion No. 8 filed on Nov. 15, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 91 pages.416Quadrant Opposition to Nektar Responsive Motion No. 8 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 41 pages.417Quadrant Opposition to Nektar Responsive Motion No. 9 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 116 pages.418Quadrant Opposition to Nektar Substantive Motion No. 2 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 159 pages.419Quadrant Opposition to Nektar Substantive Motion No. 3 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 158 pages.420Quadrant Opposition to Nektar Substantive Motion No. 4 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 91 pages.421Quadrant Opposition to Nektar Substantive Motion No. 5 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 73 pages.422Quadrant Opposition to Nektar Substantive Motion No. 6 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 103 pages.423Quadrant Opposition to Nektar Substantive Motion No. 7 filed on Feb. 6, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 185 pages.424Quadrant Reply on Responsive Motion No. 1 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 14 pages.425Quadrant Reply on Substantive Motion No. 1 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 14 pages.426Quadrant Reply on Substantive Motion No. 2 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 15 pages.427Quadrant Reply on Substantive Motion No. 3 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 4 pages.428Quadrant Reply on Substantive Motion No. 4 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 14 pages.429Quadrant Reply on Substantive Motion No. 5 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 14 pages.430Quadrant Reply on Substantive Motion No. 6 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 9 pages.431Quadrant Reply on Substantive Motion No. 7 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 13 pages.432Quadrant Reply on Substantive Motion No. 8 filed on Mar. 13, 2005, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 9 pages.433Quadrant Reply to the Notice of Opposition to European Publication No. 0773781B1, the European equivalent of U.S. Appl. No. 08/349,029 (to which the instant application claims priority), submitted Jun. 27, 2005, 27 pages.434Quadrant Responsive Motion No. 1 filed on Dec. 10, 2004, submitted in the ongoing interference proceeding involving U.S. Patent No. 6,290,991 (Roser et al.), to which the instant application claims priority, 76 pages.435Quan, C. (Jul. 1995). Protein Science 4(2):p. 148, Abstract No. 490-T.436Ramanujam, R. et al., (193). "Ambient-Temperature-Stable Molecular Biology Reagents," Biotechniques 14(3):470-473.437Remington: The Science and Practice of Pharmacy, A. R. Gennaro, 19th edition, Mack Publishing Company, Easton, Pennsylvania 18042, pp. 1517-1518 (1995).438Remington's Pharmaceutical Sciences, 18th edition., Alphonso R. Gennaro (Ed), Mack Publishing Company, "Chapter 88: Powders", pp. 1615-1632 (1990).439Reynolds, T.M., (1965). "Chemistry of Nonenzymic Browning II," Adv. Food Res. 14:167-283.440Ringe, D. et al., (Sep. 2003). "The �Glass Transition� in Protein Dynamics: What it is, Why it Occurs, and How to Exploit It," Biophys. Chem. 105(2-3):667-680, Abstract only, at http://www.ncbi.nlm.nih.gov, visited on Nov. 19, 2004.441Roempp's Encyclopedia of Chemistry, Definition of Polyol, 9th Expanded and Revised Edition, 3558-3559, with certified English Translation.442Roos, Y. (1993). "Melting and Glass Transitions of Low Molecular Weight Carbohydrates," Carbohydrate Research, 238:39-48.443Roos, Y. et al. (1990). "Differential Scanning Calorimetry Study of Phase Transitions Affecting the Quality of Dehydrated Materials," Biotechnol. Prog. 6(2):159-163.444Roos, Yrj� & Karel, Marcus, Phase Transitions of Mixtures of Amorphous Polysaccharides And Sugars 7(1) Biotechnology Progress 49-53 (Jan./Feb. 1991).445Rosenfeld, M. A. et al., (Apr. 19, 1991). "Adenovirus-Mediated Transfer of a Recombinant α-1 Antitrypsin Gene to the Lung Epithelium in Vivo," Science 252(5004):431-434.446Roser et al. (May 15, 1993) "A Sweeter Way To Fresher Food" New Scientist pp. 25-28.447Roser et al. U.S. Appl. No. 09/945,180 filed Aug. 31, 2001, (now Patent No. 6,565,871) non final Office Action dated Jul. 24, 2002.448Roser et al., U.S. Appl. No. 09/945,180 filed Aug. 31, 2001, (now Patent No. 6,545,871) Amendment Under 37 CFR �1.111 dated Nov. 25, 2002.449Roser U.S. Appl. No. 08/349,029 filed Dec. 2, 1994, Paper No. 9, Amendment under 37 C.F.R. � 1.111, mailed on Nov. 15, 1995, (Patent No. 6,290,991).450Roser U.S. Appl. No. 08/349,029, filed Dec. 2, 1994, Paper No. 40, Amendment under 37 C.F.R. � 1.111, mailed on Dec. 29, 1999 (Patent No. 6,290,991).451Roser U.S. Appl. No. 08/349,029, Notice of Allowability dated Nov. 9, 1998 (Patent No. 6,290,991).452Roser U.S. Appl. No. 08/349,029, Office Action dated May 15, 1995 (Patent No. 6,290,991).453Roser U.S. Appl. No. 08/349,029, Paper No. 26, Office Action dated Feb. 10, 1998 (Patent No. 6,290,991).454Roser U.S. Appl. No. 08/349,029, Paper No. 28, Amendment under 37 CFR � 1.111 dated Aug. 14, 1998 (Patent No. 6,290,991).455Roser U.S. Appl. No. 08/349,029, Paper No. 36, Preliminary Amendment dated Aug. 17, 1999 (Patent No. 6,290,991).456Roser U.S. Appl. No. 08/349,029, Paper No. 4, Office Action dated May 15, 1995 (Patent No. 6,290,991).457Roser U.S. Appl. No. 08/349,029, Petition for Withdrawal from Issue Pursuant to 37 C.F.R. � 1.313 (Patent No. 6,290,991).458Roser U.S. Appl. No. 08/349,029, Specification, as filed Dec. 2, 1994 (Patent No. 6,290,991).459Roser U.S. Appl. No: 08/349,029, Paper No. 24, Amendment dated Nov. 19, 1997 (Patent No. 6,290,991).460Roser, B. (1991) "Trehalose Drying: A Novel Replacement For Freeze Drying" Biopharm 4:47-53.461Roser, B. (Jul. 1991) "Trehalose, A New Approach To Premium Dried Foods," Trends in Food Sci. and Tech. pp. 166-169.462Roser, B. J. (1987). Chemical Abstracts, CAPLUS, STN, vol. 107, No. 20354, one page.463Roser, B. J. (1990). Chemical Abstracts, CAPLUS, STN, vol. 113, No. 29245, one page.464Roser, B. J. (1991). Chemical Abstracts, CAPLUS, STN, vol. 115, No. 142247, one page.465Roser, B. J. (1992). CAPLUS, STN, vol. 116, No. 54989, one page.466Roser, B. J. (1992). Chemical Abstracts, CAPLUS, STN, vol. 116, No. 127053, one page.467Roser, B. J. et al. (1992). Chemical Abstracts, CAPLUS, STN, vol. 116, No. 124367, one page.468Roser, R. Trehalose Drying: A Novel Replacement for Freeze-Drying 4(7) Biopharm 47-53 (Sep. 1991).469Roth, C. et al., (Sep. 2001). "Continuous Measurement of Drying Rate of Crystalline and Amorphous Systems During Freeze-Drying Using an In Situ Microbalance Technique," Journal of Pharmaceutical Sciences, 90(9):1345.1355.470Ryd�n, L. et al., (1992). "Effect of Polymers and Microspheres on the Nasal Absorption of Insulin in Rats," International Journal of Pharmaceutics 83:1-10.471Sakr, F. M. (Oct. 1992). "A New Approach for Insulin Delivery Via the Pulmonary Route: Design and Pharmacokinetics in Non-Diabetic Rabbits," International Journal of Pharmaceutics 86:1-7.472Sakurai, Y. (ed) (1986) "Sogo Shokuhin Jiten" Comprehensive Food Dictionary, Sixth Edition, published by Dobun Shoin, Tokyo, Japan, pp. 203-204 (Dried Eggs), 208 (Dried Eggs, or Dehydrated Eggs), and 572 (Protein Denaturation), English transition provided pp. 1-9.473Saleki-Gerhardt, A. et al., (1994). "Non-Isothermal and Isothermal Crystallization of Sucrose From the Amorphous State," Pharmaceutical Research 11(8):1166-1173.474Saleki-Gerhardt, A. et al., (Mar. 1995). "Hydration and Dehydration of Crystalline and Amorphous Forms of Raffinose," Journal of Pharmaceutical Sciences, 84(3):318-323.475Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd. ed., pp. E.10-E.17 (1989).476Sanchez, J. et al., (1989) "Recombinant System For Overexpression Of Cholera Toxin B Subunit in Vibrio Cholerae As A Basis For Vaccine Development" Proc. Natl. Acad. Sci. USA 86:481-485.477Sarkar, Nurul H. and Moore, Dan H. Immunization of Mice Against Murine Mammary Tumor Virus Infection and Mammary Tumor Development, 38, Cancer Research, 1468, Abstract, lines 12-15 (May 1978).478Schamblin and Zografi. (1998). "Enthalpy Relaxation in Binary Amorphous Mixtures Containing Sucrose," Pharmaceutical Research 15(12):1828-1834.479Schebor, C. et al., (1999). "Color Formation Due to Non-Enzymatic Browning in Amorphous, Glassy, Anhydrous, Model Systems," Food Chemistry 65:427-432.480Schluter, K. J. et al., (1984). "Pulmonary Administration of Human Insulin in Volunteers and Type 1-Diabetics," Abstract submitted to the Diabetes: A Journal of the American Diabetes Association, one page.481Schneider, Z.A. et al., (1968). "Thermostability of Enzyme in the Three-Dimensional Network of Polysaccharide Chains," Bulletin de l'Acad�mie Polonaise des Sciences, Varsovie, CL. II, vol. XVI, No. 4, pp. 203-204.482Schulter, K. J. et al., (1984). "Pulmonary Administration of Human Insulin in Volunteers and Type-1 Diabetics," Diabetes 33(Suppl.):75A, Abstract No. 298.483Sciarra, J. J. et al. (1985). "Chapter 93: Aerosols," in Remingon's Pharmaceutical Science, 18th edition, Mack Publishing Co., Gennaro, A. R., pp. 1662-1677.484Sebhatu, T. et al., (1994). "Assessment of the Degree of Disorder in Crystalline Solids by Isothermal Microcalorimetry," International Journal of Pharmaceutics104:135-144.485Sellers, S. P. et al., (Jun. 2001). "Dry Powders of Stable Protein Formulations From Aqueous Solutions Prepared Using Supercritical CO2-Assisted Aerosolization," Journal of Pharmaceutical Sciences 90(6):785-797.486Serajuddin, A. T. M. et al., (1986). "Effect of Thermal History on the Glassy State of Indapamide," J. Pharm. Pharmacol.38:219-220.487Shalaev, E. Y. et al., (Nov. 1996). "How Does Residual Water Affect The Solid-State Degradation of Drugs in the Amorphous State," Journal of Pharmaceutical Sciences, 85(11):1137-1141.488Sharma, V. K. et al., (2004). "Effect of Vaccum Drying on Protein-Mannitol Interactions: The Physical State of Mannitol and Protein Structure in the Dried State," AAPS PharmSciTech 5(1) Article 10, pp. 1-12, at http://www.aapspharmscitech.org.489Singer, Mike A. & Lindquist, Susan (Nov. 1998) "Thermotolerance in Saccharomyces cerevisiae: the Yin and Yang of Trahalose," TIBTECH 16:460-468.490Singer, Mike A. & Lindquist, Susan (Nov. 1998) Thermotolerance in Saccharomyces.491Skrabanja et al. (1994) "Lyophilization of Biotechnology Products" PDA J. Pharm. Sci. Technol. 48(6):311-317.492Slade, Louise & Levine, Harry, Non-Equilibrium Behavior of Small Carbohydrate-Water Systems 60(12) Pure and Applied Chemistry 1841-1864 (1988).493Slade, Louise & Levine, Harry, The Glassy State Phenomenon in Food Molecules J. M. V. Blanshard and P. J. Lillford eds., The Glassy State in Foods, Nottingham University Press, 35-101.(1993).494Smith, M. A. et al., (Jun. 1994). "Advanced Maillard Reaction End Products are Associated with Alzheimer Disease Pathology," Proc. Natl. Acad. Sci. USA 91(12):5710-5714.495Sokolov, A. P. et al., Glassy Dynamics in DNA: Ruled by Water of Hydration 110(14) Journal of Chemical Physics 7053-7057 (Apr. 8, 1999).496Sola-Penna, Mauro et al., Stabilization Against Thermal Inactivation Promoted by Sugars on Enzyme Structure and Function: Why Is Trehalose More Effective Than Other Sugars? 360(1) Archives of Biochemistry and Biophysics 10-14, Article No. BB980906, (Dec. 1998).497Sonner, C. et al., (Oct. 2002). "Spray-Freeze-Drying for Protein Powder Preparation: Particle Characterization and a Case Study With Trypsinogen Stability," Journal of Pharmaceutical Sciences 91(10):2122-2139.498Sperling, L. H. (1986). "Chapter 6: Glass-Rubber Transition Behavior," in Introduction to Physical Polymer Science, New York, John Wiley & Sons, pp. 224-300.499Spi Polyols� (2003). What are Polyols? What do Polyols do? What are Polyols' functionality? at http://www.spipolyols.com/whatarepolyols.html, visited on Jun. 25, 2004, one page.500SpiPHarma� , Mannogem� Mannitol, Products at http://www.spipharma.com/ProductsFolder/112MannogemManitol/112MannogemPowders.html, visited on Oct. 25, 2005, 3 pages.501Stedman'S Medical Dictionary, William & Wilkins, 26th ed., p. 1405, Definition of Polyol (1995).502Stribling, R. et al. (Dec. 1992) "Aerosol Gene Delivery in Vivo," Proc. Natl. Acad. Sci. 89:11277-11281.503Stribling, Roscoe et al., The Mouse as a Model for Cationic Liposome-Based Aerosolized Gene Delivery, 3(�) J. Biopharm. Sci. 255-263 (1992).504Stribling, Roscoe et al., The Mouse as a Model for Cationic Liposome-Based Aerosolized Gene Delivery, 3(1/2),J. Biopharm. Sci. 255-263 (1992).505Strickley, R. G. et al., (Jun. 1997). "Solid-State Stability of Human Insulin II. Effect of Water on Reactive Intermediate Partitioning in Lyophiles from pH 2-5 Solutions: Stabilization Against Covalent Dimer Formation," Journal of Pharmaceutical Sciences 86(6):645-653.506Strom, A. R. and Kaasen, I. (1993). "Trehalose Metabolism in Escherichia coli: Stress Protection and Stress Regulation of Gene Expression," Molecular Microbiology 8(2):205-210.507Stubberud, L. et al., (1998). "The Use of Gravimetry For The Study of the Effect of Additives on The Moisture-Induced Recrystallisation of Amorphous State," International Journal of Pharmaceutics 163:145-156.508Sukenik, C. N. (1975). "Enhancement of a Chemical Reaction Rate by Proper Orientation of Reacting Molecules in the Solid State," J. Am. Chem. Soc. 97:5290-5291.509Susan Budavari et al., The Merck Index, ONR-57 (12th ed. 1996).510Sussich, F. et al., (2001). "Reversible Dehydration of Trehalose and Anhydrobiosis: From Solution State to an Exotic Crystal?" Carbohydrate Research 334:165-176.511Takahashi et al., (1990) "Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs" Nature 344:873-875.512Takiff, H. E. et al., (Jul. 1984). "Cloning and Physical Mapping of Enteric Adenoviruses (Candidate Types 40 and 41)," Journal of Virology 51(1):131-136.513Tarelli, E. et al., (1987). "Additives to Biological Substances. III. The Moisture Content and Moisture Uptake of Commonly Used Carrier Agents Undergoing Processing Conditions Similar to Those Used in the Preparation of International Biological Standards," Journal of Biological Standardization 15:331-340.514Thatcher, E. (Jan. 5, 2002), Quantitation of Virus at http://www.sonoma.edu/users/t/thatcher/biol383/lab.htm visited on Nov. 1, 2004, 4 pages (last updated Jan. 5, 2002).515The Condensed Chemical Dictionary, (1966). "Definition of �Glass�," 7th edition, (1966) revised by A. Rose, State College, Pa., Reinhold Publishing Corporation, New York, p. 448.516The Merck Index, under Section entitled "Organism Name Reactions," p. ONR-57, at "Maillard Reaction" (10th ed. 1983).517The New Encyclopaedia Britannica (1985). "Atmospheric Humidity and Precipitation," under "Climate and Weather," vol. 16, 15th edition, Encyclopaedia Britannica, Inc., pp. 476-479.518Theory, Sec. 14.1 entitled "Psychrometric Chart (10-20� C based on Barometric Pressure of 101.325 kPa.,") p. 283.519Timko et al. (1984) "Thermal Analysis Studies of Glass Dispersion Systems" Drug Devel. Ind. Pharm. 10:425-451.520Timsina, T. et al., (1994). "Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers," International Journal of Pharmaceutics 101:1-13.521To, E. et al. (1978). "Collapse, a Structural Transition in Freeze Dried Carbohydrates," J. Fd. Technol. 13:567-581.522To, E. et al., (1978). "'Collapse', a Structural Transition in Freeze Dried Carbohydrates," J. Fd. Technol. 13:567-581.523Townsend, M. W. et al., (1988) "Use of Lyoprotectants in the Freeze-Drying of a Model Protein, Ribonuclease A," Journal of Parenteral Science & Technology 42(6):190-199.524Toyama, A. (ed), (1986) Handbook of Natural Product for food processing, 9th Edition, Osaka, Japan, Shokuhin to Kagaku Sha, pp. 384 and 495 (ISBN4-87994-048-8).525Tsourouflis, S. et al. (1976). "Loss of Structure in Freeze-Dried Carbohydrates Solutions: Effect of Temperature, Moisture Content and Composition," J. Sci. Fd. Agric. 27:509-519.526Uedaira, H. et al., (1980). "The Effect of Sugars on the Thermal Denaturation of Lyzozyme," The Chemical Society of Japan 53:2451-2455.527Ulrich, Anne A. Biophysical Aspects of Using Liposomes as Delivery Vehicles 22(2) DNA-Lipid Structures 129-150 (Apr. 2002).528Underwood, Stephen L. et al., A Novel Technique for the Administration of Bronchodilator Drugs Formulated as Dry Powders to the Anaesthetized Guinea Pig, 26 J. Pharm. Methods 203-210 (1991).529Underwood, Stephen L. et al., A Novel Technique for the Administration of Bronchodilator Drugs Formulated as Dry Powders to the Anaesthetized Guinea Pig, 26 J. Pharm. Methods 203-210(1991).530United States Patent and Trademark Office, Board of Patent Appeals and Interferences, Patent Interference No. 105,219, Quadrant Drug Delivery Ltd v. Nektar Therapeutics, Paper No. 140, rendered Dec. 26, 2007, Decision �Bd.R. 125 �on Motions, 44 pages total.531United States Patent and Trademark Office, Board of Patent Appeals and Interferences, Patent Interference No. 105,219, Quadrant Drug Delivery Ltd v. Nektar Therapeutics, Paper No. 141, rendered Dec. 26, 2007, Order - Bd. R. 7(a), Bd. R. 128, Expunging Papers -, 2 pages total.532United States Patent and Trademark Office, Board of Patent Appeals and Interferences, Patent Interference No. 105,219, Quadrant Drug Delivery Ltd v. Nektar Therapeutics, Paper No. 142, rendered Dec. 26, 2007, Judgment �Bd.R. 127 �, 2 pages total.533Uritani, M. et al., (1995). "Protective Effect of Disaccharides on Restriction Endonucleases During Drying Under Vacuum," J. Biochem. 117:774-779.534US 5,849,884, 12/1998, Woiszwillo et al. (withdrawn)535Vain et al., (1993) "Development of the particle inflow gun" Plant Cell, Tissue and Organ Culture 33:237-246.536van de Beek, M. J. et al., (1969). "Preservation of the Enzymatic Activity of Rennin During Spray Drying and During Storage and The Effect of Sugars and Certain Other Activities," Neth. Milk Dairy J. 23(1):46-54.537Vavelyuk, O.L. et al., (19990. "Thermostability of DNA and Its Association With Vitrification," Tsitologiya 41(11):958-965.538Vidgren, M. et al., (1988). "In Vitro and in Vivo Deposition of Drug Particles From Pressurized Aerosol and Dry Powder Inhaler," Drug. Devel. Indust. Pharm. 14(15-17):2649-2665.539Vidgr�n, M. T. et al., (1987). "Comparison of Physical and Inhalation Properties of Spray-Dried and Mechanically Micronized Disodium Cromoglycate," International Journal of Pharmaceutics 35:139-144.540Vitek, M.P., et al., (May 1994). "Advanced Glycation End Products Contribute to Amyloidosis In Alzheimer Disease," Proc. Natl. Acad. Sci. USA 91:4766-4770.541Vromans, H. et al., (1987). "Studies on Tableting Properties of Lactose. VII. The Effect of Variations in Primary Particle Size and Percentage of Amorphous Lactose in Spray Dried Lactose Products," International Journal of Pharmaceutics 35:29-37.542Wang, et al. eds. (1993). Stability and characterization of protein and peptide drugs, Table of contents, 6 pages.543Welsh, D. T. (Aug. 1992). "The Role of Compatible Solutes In the Adaptation and Survival of Escherichia coli," Ph.D. Thesis Submitted to Department of Biological Sciences, University of Dundee. pp. 1-262.544Welsh, D. T. et al., (1991). "The Role of Trehalose in the Osmoadaptation of Escherichia coli NCIB 9484: Interaction of Trehalose, K+ and Glutamate During Osmoadaptation in Continuous Culture" (1991)J. Gen. Microbiol. 137:745-750.545White, G. W. et al., (1966). "The Glassy State in Certain Sugar-Containing Food Products," J. Food Technol. 1:73-82.546Whittier, E. Lactose and its Utilization: A Review, 27(7) J. Dairy Sci. 505-537 (Jul. 1944).547Wigley, F. M. et al., (1971). "Insulin Across Respiratory Mucosae by Aerosol Delivery," Diabetes 20(8):552-556.548William and Leopold (1979). "The Glassy State in Corn Embryos" Plant Physiology 89:977-981.549Williams, M. L. et al., (Jul. 20, 1955). "The Temperature Dependence of Relaxation Mechanisms in Amorphous Polymers and Other Glass-Forming Liquids," Journal of the American Chemical Society 77:3701-3707.550Wolanczyk, (Jan./Feb. 1989). "Differential Scanning Calorimetry Analysis of Glass Transitions," Cryo-Letters 10(1):73-76.551Wolff, J. A. et al., (Nov. 1989) "Grafting Fibroblasts Genetically Modified to Produce L-Dopa in a Rat Model of Parkinson Disease," Proc. Natl. Acad. Sci.86:9011-9014.552Wyde, P. R. (Jun. 1984). "Pulmonary Deposition and Clearance of Aerosolized Interferon," Antimicrob. Agents Chem. 25(6):729-734.553Xi, Y. G. et al., (1992). "Amphotericin B Treatment Dissociates in Vivo Replication of the Scrapie Agent From PrP Acummulation," Nature 356:598-601.554Yamazaki, S. et al., (1989). "Highly Sensitive Enzyme Immunoassay of Human Interferon-β1." Journal of Immunoassay 10(1):57-73.555York, Peter, Powdered Raw Materials: Characterizing Batch Uniformity Respiratory Drug Delivery IV 83-91 (1994).556Yoshida, H. et al., (May 1979). "Absorption of Insulin Delivered to Rabbit Trachea Using Aerosol Dosage Form," Journal of Pharmaceutical Sciences 68(5):670-671.557Yoshinari, T. et al., (2002). "Moisture Induced Polymorphic Transition of Mannitol and Its Morphological Transformation," International Journal of Pharmaceutics, 247:69-77.558Yoshioka, M. et al., (Dec. 1994). "Crystallisation of Indomethacin From the Amorphous State Below and Above Its Glass Transition Membrane," Journal of Pharmaceutical Sciences 83(12):1700-1705.559Yoshioka, S. et al., (1999). "The Effect of Excipients on the Molecular Mobility of Lyophilized Formulations, as Measured by Glass Transition Temperature and NMR Relaxation-Based Critical Mobility Temperature," Pharmaceutical Research 16(1):135-140.560Yu, E. et al. (1995). "Structural Glass Transitions and Thermophysical Processes in Amorphous Carbohydrates and Their Supersaturated Solutions," J. Chem. Soc. Faraday Trans. 91(10):1511-1517.561Zubay, G. Biochemistry, 2nd ed., pp. 39, 169 (1988).562Zubay, G. Biochemistry, Second Edition, p. 169, Table 5-6 Major Steroid Hormones (1988).563Zubay, G. Biochemistry, Second Edition, pp. 216-232 "Structural Properties of DNA" (1988). Referenziert von Zitiert von PatentEingetragen Ver�ffentlichungsdatum Antragsteller TitelUS8475845 *14. Juli 20062. Juli 2013Map Pharmaceuticals, Inc.Method of particle formation* Vom Pr�fer zitiertKlassifizierungen US-Klassifikation424/499, 424/489Internationale KlassifikationA61K9/16, A61K9/50, A61K9/14 UnternehmensklassifikationA61K9/1623, A61K9/0021, A61K9/145 Europ�ische KlassifikationA61K9/14H4, A61K9/16H4B, A61K9/00M5BJuristische Ereignisse DatumCodeEreignisBeschreibung6. M�rz 2006ASAssignmentOwner name: ELAN DRUG DELIVERY LIMITED, UNITED KINGDOMFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QUADRANT HEALTHCARE (UK) LIMITED;REEL/FRAME:017307/0139Effective date: 20020919Owner name: QUADRANT DRUG DELIVERY LIMITED, UNITED KINGDOMFree format text: CHANGE OF NAME;ASSIGNOR:ELAN DRUG DELIVERY LIMITED;REEL/FRAME:017307/0125Effective date: 20030728Owner name: QUADRANT HEALTHCARE (UK) LIMITED, UNITED KINGDOMFree format text: CHANGE OF NAME;ASSIGNOR:QUADRANT HOLDINGS CAMBRIDGE LIMITED;REEL/FRAME:017303/0767Effective date: 20000724Owner name: QUADRANT HOLDINGS CAMBRIDGE LIMITED, UNITED KINGDOFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSER, BRUCE J.;KAMPINGA, JAAP;COLACO, CAMILO;AND OTHERS;REEL/FRAME:017307/0128;SIGNING DATES FROM 19950201 TO 19950206Owner name: QUADRANT HOLDINGS CAMBRIDGE LIMITED,UNITED KINGDOMFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSER, BRUCE J.;KAMPINGA, JAAP;COLACO, CAMILO AND OTHERS;SIGNED BETWEEN 19950201 AND 19950206;REEL/FRAME:17307/128Free format text: CHANGE OF NAME;ASSIGNOR:ELAN DRUG DELIVERY LIMITED;REEL/FRAME:17307/125Owner name: QUADRANT DRUG DELIVERY LIMITED,UNITED KINGDOMOwner name: ELAN DRUG DELIVERY LIMITED,UNITED KINGDOMFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QUADRANT HEALTHCARE (UK) LIMITED;REEL/FRAME:17307/139Owner name: QUADRANT HEALTHCARE (UK) LIMITED,UNITED KINGDOMFree format text: CHANGE OF NAME;ASSIGNOR:QUADRANT HOLDINGS CAMBRIDGE LIMITED;REEL/FRAME:17303/767Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSER, BRUCE J.;KAMPINGA, JAAP;COLACO, CAMILO;AND OTHERS;SIGNING DATES FROM 19950201 TO 19950206;REEL/FRAME:017307/0128DrehenOriginalbildGoogle-Startseite - Sitemap - USPTO-Bulk-Downloads - Datenschutzerkl�rung - Nutzungsbedingungen - �ber Google Patente - Feedback gebenDaten bereitgestellt von IFI CLAIMS Patent Services.© 2012 Google